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Resumo 
 
 
A sinalização paracrina e autocrina desempenha um papel importante 
na proliferação, diferenciação e apoptose das células epiteliais 
mamárias. Apesar de este facto ser globalmente aceite os 
mecanismos pelos quais estes processos ocorrem ainda não são 
totalmente compreendidos. Em particular, a acção dos estrogénios 
através do receptor de estrogénio alpha (ERα) e beta (ERβ) afectam 
profundamente a proliferação e diferenciação; no entanto o papel do 
ERβ nestes processos é ainda pouco conhecido. 
Com o objectivo de melhor compreender os mecanismos de 
sinalização envolvidos na diferenciação das células epiteliais 
mamárias fez-se a recolha do meio condicionado (CM) de células 
HC11 nas 3 etapas de diferenciação: stem-cell like (SCL), pre-
differenciadas (PD) e funcionalmente diferenciadas (D). Em seguida, 
as proteínas do CM foram separadas com recurso a SDS-PAGE e 
2D-PAGE e identificadas por MALDI-TOF/TOF. Os nossos resultados 
mostram que células em SCL segregam factores que possuem um 
papel pró-angiogenico/invasor e de sobrevivência, bem como outros 
factores que desempenham a função oposta. Estes resultados estão 
de acordo com o estado activo de proliferação e migração observado 
nestas células. Com o inicio da diferenciação (células em PD e D) 
ocorreu uma mudança nas proteínas mais secretadas, sendo 
possível observar um aumento do nível de proteínas que regulam a 
adesão e apoptose.  
Para estudar os mecanismos regulados pelo ERβ, o CM de células 
não diferenciadas, bem como de células a entrar em diferenciação (-
EGF) e totalmente diferenciadas (D) foi recolhido após a activação do 
ERβ por ligandos. As proteínas presentes no CM foram novamente 
separadas por SDS-PAGE e 2D-PAGE e identificadas por MALDI-
TOF/TOF. Os nossos resultados mostraram uma diferença nos níveis 
de proteínas segregadas em SCL+EGF quando comparado com 
SCL-EGF, indicando que as vias metabóicas que mantêm as células 
numa condição indiferenciada como o EGF também comunicam com 
a sinalização activada por ERβ. Além disso, em concordância com 
SCL-EGF, as células em D, as proteínas reguladas pelo ERβ 
estavam relacionadas com adesão e apoptose indicando que o 
estado celular de diferenciação modula a sinalização do ERβ; sendo 
que o já identificado papel de supressor tumoral do ERβ é 
desencadeado apenas quando as células começam a diferenciar. 
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abstract 
 
Paracrine and autocrine signalling play an important role in proliferation, 
differentiation and apoptosis of mammary epithelial cells. Despite this fact 
being accepted unanimously, the mechanisms by which these processes occur 
are not fully understood. In particular, estrogens acting through estrogen 
receptors alpha (ERα) and beta (ERβ) profoundly affect proliferation and 
differentiation; however, knowledge about ERβ role in these processes is still 
unclear.  
With the goal to best understand the signalling mechanisms involved in 
mammary epithelial cells differentiation, we collected the conditioned media 
(CM) of HC11 cells in the three stages of differentiation: stem-cell like (SCL), 
pre-differentiated (PD) and functionally differentiated (D). Next, the proteins in 
the CM were separated using SDS-PAGE and 2D-PAGE and identified by 
MALDI-TOF/TOF. Our results showed that SCL cells secrete factors with pro-
angiogenic/invasion and survival roles as well as factors with the opposite 
functions. These results were in agreement with the controlled active 
proliferation and migration observed in these cells. With the beginning of 
differentiation (PD and D cells) a change in the most secreted proteins 
occurred, being possible to observe a raise in the levels of proteins that 
regulate adhesion and apoptosis.  
To study the mechanisms regulated by ERβ, the CM of SCL cells either kept 
undifferentiated (+EGF), entering differentiation (-EGF) or fully differentiated (D) 
was collected following ERβ ligand activation. Proteins present in the CM were 
once again separated by SDS-PAGE and 2D-PAGE and identified by MALDI-
TOF/TOF. Our results showed a difference in the levels of proteins secreted in 
SCL+EGF compared to SCL-EGF, indicating that pathways that maintain the 
undifferentiated SCL stage such as EGF also cross talk with ERβ signalling. 
Moreover, similar to SCL-EGF, in D cells, proteins regulated by ERβ were cell 
adhesion and apoptosis related proteins indicating that the cellular state of 
differentiation modulates ERβ signalling; being that the previously identified 
tumour suppressor role of ERβ is triggered only with the beginning of 
differentiation. 
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1. The mammary gland 
 
All female mammals have a mammary gland with the main purpose to feed their 
infants in the earlier stages or their lives. The mammary gland is a very specialized 
secretory gland that when fully developed is composed of the alveolus grouped into 
lobules, where milk is produced, and ducts, the canals that transport milk from lobules to 
the nipple. Alveoli and ducts are highly differentiated epithelial structures surrounded by 
fatty tissue (Fig. 1). The mammary gland develops after birth and undergoes several 
development stages to reach its final mature form and function. Five different stages in 
mammary gland development can be identified [1]: embryonic, pre-pubertal, pubertal, 
sexually mature adult, pregnancy and lactation (Fig. 2).   
 
 
 
Figure 1- Schematic representation of the mammary gland. Source: www.cancer.org 
 
 
During the embryonic phase, mammary placodes are formed in the ventral zone of the 
embryo where the nipples will grow. The placodes give rise to a rudimentary ductal system 
that remains unaltered until puberty. Therefore, throughout pre-puberty, the mammary 
gland maintains a growth rate similar to the rest of the body [2-4]. 
 
 
7 
 
 
Figure 2– Development stages of the mammary gland. Source: Robinson, G., 2005. 
TEB: Terminal end bud. 
 
 
It is with the beginning of puberty, the establishment of a menstrual cycle and dramatic 
increase in ovarian estrogen (E2) and progesterone (Pg) levels that the majority of changes 
in the mammary gland occur. Ductal ramification resumes, permitting the formation of a 
more complex network with the formation of secondary ducts occupying a large amount of 
fat area, like branches of a tree. Pregnancy, with an increase of Pg and prolactin (Prl), 
initiates the last stage of maturation with tertiary ductal ramification and alveolar 
differentiation, thus preparing the gland for lactation. Finally, after weaning, and in 
response to the lack of suction stimuli, alveoli collapse, cells are removed by apoptosis and 
the mammary gland returns to a state similar to before pregnancy and ready to undergo a 
new proliferation-differentiation-death cycle (Fig. 2). It is postulated that the regenerative 
capacity of the mammary gland is possible thanks to mammary stem cells (SC) and 
although such cell has not been identified, several progenitor cells capable of originating 
mammary gland structures such as alveoli and ducts, have been isolated [5-7]. 
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1.1. Hormonal regulation of mammary gland development  
 
Hormonal regulation of mammary gland development can be divided into 2 processes: 
Growth of the ductal tree and alveolar differentiation. 
I. Growth of the ductal tree: The first step in mammary gland development is 
elongation of the ducts. Ductal elongation is the result of proliferation in the tips of ducts, 
known as terminal end buds (TEBs). Ductal proliferation is induced by E2 and occurs 
through a paracrine mechanism, where binding of E2 to estrogen receptor alpha (ERα) 
activates secretion of amphiregulin (Areg) which then activates proliferation of 
neighbouring epithelial cells (paracrine mechanism) [8]. For this process to occur, 
induction of insulin-like growth factor 1 (IGF1) by growth hormone (GH) in the stroma is 
also necessary [9-10].  
A normal ductal ramification requires the presence of estrogen (E2) and ERα while 
estrogen receptor beta (ERβ) is not fundamental [11]. Studies carried out in ovariectomized 
mice (no E2) or ERα null mice (ERα-/-), showed that administration of epidermal growth 
factor (EGF) leads to a normal mammary development [12]. Considering these facts and 
knowing that administration of E2 leads to EGF receptor (EGFR) activation by Areg, it 
seems clear that EGFR pathway is important for ductal growth [12-13]. The enzyme in 
charge of releasing Areg to make it available for the paracrine effects is a member of 
desintegrin and metalloproteinase family (ADAM) called ADAM-17 [2, 14]. Once EGFR 
is activated, it guides the release of fibroblast growth factors (FGFs) particularly FGF2 and 
FGF7 to mediate proliferation and TGF-β to inhibit growth of certain areas of the duct, 
thus influencing the architecture of the ductal branches [15-16]. 
One model that tries to explain these mechanisms suggest that the luminal sensor cells 
(expressing ERα) upon stimulation by E2 secrete membrane bound Areg, which is 
liberated by ADAM17 promoting proliferation. Stem cells are induced to proliferate 
creating progenitor cells that can originate myoepthelial and epithelial cells as well as 
luminal cells. In this process FGF/FGFR and EGF/EGFR have an important role. TEB 
growth and consequent fat pad invasion is only possible through extracellular matrix 
(ECM) degradation by metalloproteinases (MMPs) secreted by activated stromal cells (Fig. 
3). 
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Figure 3– Model of the ductal tree growth. Source: Brisken, C., 2007. A) TEB B) Detail of TEB 
 
 
EGFR is a tyrosine kinase receptor that participates in several signalling pathways 
associated with proliferation and cell survival. When activated by one of its ligands it 
dimerizes with another EGFR or with a related receptor (ErbB2, ErbB3 or ErbB4) [17]. 
Within different EGFR ligands, Areg is the only one upregulated in puberty (by E2) and it 
was identified as the only EGFR ligand necessary for mammary maturation [13-14].  
Invasion of the mammary fat pad by epithelial cells is necessary for ramification and 
growth of the ducts. An increase of ECM-degrading proteases activity leads to ramification 
in kidneys, lungs, salivary glands pancreas and mammary gland. EGFR activation also 
leads to the release of proteases that degrade ECM allowing cell invasion of the 
surrounding fat tissue [18]. Within the ECM degradating group of enzymes, the most 
important are MMPs which are zinc dependent enzymes capable of degradating ECM 
proteins such as collagens and laminins. However some studies have indicated that a high 
raise in their activity could lead to ductal hyperplasia and even to tumorogenesis [18]. An 
important role in bifurcation of the ducts is played by collagenases, which degradate 
A 
B 
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collagen type I preventing bifurcation. On the contrary, inhibition of collagenases leads to 
collagen type I deposition facilitating bifurcation [18]. MMPs also affect ramification 
because they can interfere with ligand-receptor communication causing proliferation or 
apoptosis [13, 18-19]; ECM degradation may produce fragments with proliferative and 
morphogenic effect [7, 20]; and degradate cell adhesion molecules facilitating cell 
detachment and invasion [21-22].  
Related to MMPs it is important to mention their inhibitors, tissue inhibitors of 
metalloproteinases (TIMPs) that in most cases stop ramification because they bind to 
MMPs and inhibit invasion [18].  
 
II. Alveolar differentiation: When females reach their sexual maturity and establish regular 
menstrual cycles the ovaries release regular amounts of Pg. In pregnancy this function is 
sustained by the placenta. With the development of pregnancy the pituitary releases Prl. 
Both Pg, and later on Prl have an important role in alveolar differentiation [23]. 
Pg activates progesterone receptor (PR) and induces further ramification and alveolar 
differentiation. Pg effects on the mammary gland occur through paracrine/autocrine 
mechanisms, where activation of PR leads to secretion of Wnt 4 and receptor activator of 
NFκB ligand (RANKL) to induce proliferation and survival of alveolar cells, respectively 
[5, 24].  
Alveolar differentiation is completed reaching the end of pregnancy and sustained 
throughout lactation. Prl and its receptor PrlR are also implicated in the expression of 
several proteins including RANKL. This protein and its receptor (RANK) participate in 
alveolar maturation and can also inhibit apoptosis [25].  
Another factor involved in these mechanisms is Igf2 that is thought to participate in 
alveogenesis. Heregulin 1 (HRG1, an EGF family member) that activates ErbB receptors 
mediates alveolar differentiation and proliferation but can be replaced by other factors [26-
27]. 
Brisken et al. [2], suggest that in alveolar differentiation stem cells originate bipotent 
progenitors from which the myoepithelial and luminal lineages will be derived. In this 
process FGF/FGFR and alternatively, EGF/EGFR are involved. A luminal sensor cell is 
stimulated by Pg leading to WNT and RANKL secretion which, in turn stimulate 
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proliferation and survival in neighbour cells. Functional differentiation of alveolar cells is 
achieved in the fully differentiated epithelium by Prl/PrlR (fig. 4). 
 
Figure 4- Model of alveolar differentiation. Source: Brisken, C., 2007. 
 
 
Besides regulating paracrine pathways described previously Prl ligation to its receptor 
initiates an intracellular response. After Prl binding, PrlR dimerization happens and janus 2 
kinase (JAK2) activation occurs, this in turn leads to signal transducer and activator of 
transcription 5 a (STAT5a) phosphorylation. STAT5a allows the expression of some 
proteins that constitute milk such as β-casein as well as suppressors of cytokine signalling 
(SOCS) to promote survival [27-29]. 
Although there is no role assigned to ERα in the differentiation process of alveoli, ERβ 
has a role in maintaining the epithelium through control of cell adhesion proteins such as 
cadherins and integrins. In fact, mammary glands from pregnant and lactating ERβ null 
mice (ERβ -/-) where able to produce milk. However, they showed alterations in the 
alveolar epithelial cells, and the basal membrane, indicating that ERβ participates in 
alveolar differentiation [30].  
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2. Cell adhesion and differentiation in the mammary gland 
 
The current notion of the ECM considers that rather than act only as a barrier and 
substrate to cells, it also communicates and interacts with them. This communication can 
occur due to the connection of certain molecules present in the ECM to adhesion proteins 
such as integrins and modulation of cadherins. Alterations in cell adhesion mechanisms 
can lead to carcinogenesis [31]. Cadherins are a superfamily of transmembrane adhesion 
molecules, which participate in cellular cohesion, apoptosis inhibition and cellular 
signalling. Within this family it is important to highlight E-cadherins, proteins that 
influence morphology and polarization of epithelial cells. Thus, it was proved that loss of 
E-cadherin is correlated to carcinogenesis and metastasis progression in breast cancer. E-
cadherins interact with catenins through their citoplasmatic domain and form bonds with 
the cytoskeleton called adherens junctions [32-33].  
Integrins are transmembrane proteins that tie cells to ECM. The connection is once 
again made to the cytoskeleton of the cell through interaction of integrins cytosolic 
domains with a varying group of proteins [31]. Several studies have demonstrated that 
integrins have an active role in ductal ramification namely, α2 integrin in mice and α3 
integrin in human cells. The different combinations of ligands (ECM proteins) and integrin 
receptors will lead to a stronger or weaker binding to cytoskeleton, activation of different 
signalling cascades and ultimately to the level of adhesion/invasion of cells. Within the 
integrin ligands the most relevant are laminins collagens and fibronectins. Collagen 
binding to integrin receptors besides mediating ductal ramification also participates in the 
production of basal membrane that surrounds the ducts [34-36].  
Although integrins and cadherins are important in morphogenesis of mammary ducts 
and alveoli they are not the only receptors that participate in this process. It is important to 
refer the participation of other receptors such as β 1,4 glactosyltransferase and 
dystroglycan [37-38]. Moreover, expression and activity of E-cadherin as well as several 
integrins is regulated by E2 and EGFR ligands [33, 39-40], and their availability in the cell 
membrane is dependent of expression levels, as well as turnover rate and endocytosis [33].   
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3. Estrogen receptors 
 
There are two estrogen receptors (ERs) that mediate estrogen action, ERα and ERβ. 
These receptors more than isoforms, are two distinct proteins codified by genes in different 
chromosomes. ERs are ligand activated transcription factors, members of the 
steroid/retinoid receptor family and like other members of this family are constituted by six 
functional and structural domains (A to F) [11, 41]. On the N’-terminal, the A/B domain 
functions as a transcriptional activator. Domain C or DNA binding domain (DBD) is 
responsible for mediating binding to Estrogen Response Elements (EREs) on the DNA. 
Between ERα and ERβ, there is a 96% homology on the DBD, suggesting that both ERs 
bind with the same affinity to EREs. The D domain is a region not well characterized. 
Ligand binding occurs in E/F Domain or Ligand Binding Domain (LBD). ERα and ERβ 
exhibit a 53% homology in the LBD (Fig. 5) which could indicate that although they bind 
the endogenous hormone E2 with the same affinity, they have different affinities for other 
ligands [42-43]. Two of the compounds that are used as selective agonists of ERα and ERβ 
are 4,4’,4’’- (4-propyl-(1H)-pyrazole-1,3,5-triyl)trisphenol (PPT) which is 410-fold more 
selective for ERα over ERβ and 2,3-bis (4-hydroxy-phenyl)-propionitrile (DPN), 72-fold 
more selective for ERβ rather than ERα [44-45]. ER selective agonists and antagonists are 
important tools to help elucidate ER role in mammary development and have been 
proposed as possible alternative therapy for breast cancer [46]. In addition, ERs have two 
activation functions (AFs) AF-1 in the DBD which is a consensus phosphorylation site 
activated in the absence of ligand, and AF-2 which is activated in a ligand dependent 
manner.   
 
 
Figure 5– Comparison between human ERα and ERβ domains. Source: Weihua, Z., et al., 2003. 
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Estrogen and ERs regulate several cellular processes through distinct pathways. Ligand 
activation of ERs leads do receptor dimerization and direct binding to DNA at the 
promoter region ERE (Fig. 6A), modulating gene transcription. However, ER activation 
can interact with transcription factors such as AP-1 (Fig. 6B) or SP-1 and as a result, 
modulate gene expression indirectly. ERα and ERβ can present different/opposite effects 
on AP-1 or SP-1 regulated promoters. ER-ligand binding may also cause rapid effects 
through non genomic mechanisms which are not well understood [47]. In addition, ER 
activation can also be ligand independent as for example, growth factor signalling (i.e. 
EGF/EGFR) may lead to ER phosphorylation in AF-1. This mechanism is thought to be 
responsible for hormone independent growth of ER positive breast cancers.  
 
 
 
 
Figure 6– Scheme of transcription activation by ERs. A) Direct binding to promoter region ERE;  
B) Indirect binding to the promoter region AP-1. Source: Schiff, R. and Osborne, C.K. 2005. 
 
 
The two ERs are differently expressed in the different body tissues. ERα is 
predominant in the uterus, mammary gland, testis, pituitary while ERβ is mainly 
encountered in the prostate and ovaries. In the mammary gland, it is possible to see a 
different distribution of both ERs. ERα is found in the ductal epithelium and ERβ is 
expressed in the ductal and lobular epithelium and also in the stroma [1, 11]. 
A 
B 
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4. Breast Cancer 
 
Of all the different types of cancer, breast cancer has the second highest incidence rate 
and the second highest death rate in western women [48]. Normally, in breast cancer, 
changes that transform normal cells in cancer cells occur in the alveolar or ductal 
epithelium and are associated to genetic or epigenetic alterations in normal signalling 
pathways that regulate proliferation, survival and differentiation  [49]. In rare cases, this 
transformation can occur in fat tissue.  
Despite all efforts to understand the mechanisms involved in this pathology there is still 
a lot to unravel and this is due to the heterogeneity of the disease. There are two 
hypotheses, not necessarily exclusive that aim to explain breast cancer heterogeneity [50]. 
One of the theories considers that each breast cancer subtype initiates in different types of 
cells (cell of origin model; Fig. 7A). The second theory refers that the cell of origin can be 
the same to different subtypes and the transformation is due to a series of genetic or 
epigenetic events (subtype transformation event model; Fig. 7B). Within these hypotheses, 
the existence of transformed stem cells (cancer stems cells) with capacity to differentiate 
into different epithelial subtypes is the most accepted nowadays and serves also to explain 
the plasticity of cancers that allows them to respond to environmental pressure and acquire 
resistance to therapy [50-51]. 
 
 
Figure 7– Origin hypothesis for the several breast cancer subtypes. A) Cell of origin model;  
B) Tumor subtype–specific transforming event model. Source: Polyak, K., 2007. 
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Through genetic profile analyses it was possible to group mammary tumours into five 
molecular subtypes that are transversal to all ethnicity [52-53]: luminal A and luminal B 
(both expressing ER), HER2
+
/ER
-
,
 
basal-like (ER, PR and HER2 negative), and normal 
breast-like. Such classification is useful as in general, treatment of patients is administered 
according to the type of receptors expressed (i.e. ER antagonists, HER2 inactivating, 
antibodies). Luminal type can have expression of ER, PR and varying degrees of HER2. 
Luminal A tumours have high expression of ERα and PR and best prognosis; while basal-
like tumours are the less differentiated, share expression of genes with mammary stem cell 
markers and have the worse prognosis and lower survival rate [54]. Due to the relatively 
novel discovery of ERβ, its potential as predictive factor is still under investigation. 
 
 
4.1. Breast cancer and ER expression  
 
Stimulation of normal mammary epithelium with E2 leads to increased proliferation 
and studies have demonstrated a correlation between breast cancer in humans and a long 
exposure to E2. Hence, E2 exposure has been regarded as a risk factor in breast cancer [11, 
55]. This relation can be observed for example, by the fact that 70% of breast cancers 
express ERs and breast cancer occurs in women never before puberty and that women with 
a long fertile period present a higher risk [56]. Women with high E2 blood levels are also a 
risk group [57]. On the other hand, women with early menopause due to natural causes or 
castration have a lower risk of developing breast cancer [56].  
 The role of ERα inducing proliferation in breast cancer is well established and 
expression of this receptor is presently the only factor considered to indicate patient 
treatment with ER antagonists like tamoxifen or aromatase inhibitors to reduce E2 body 
levels. However, most cancers will develop resistance to this therapy and there is a need to 
find new treatments [55]. Studies in cell lines showed that ERβ inhibits proliferation and 
induces apoptosis and is important in maintaining differentiation [40, 58]. Therefore, it has 
been proposed that treatment with ERβ agonists could be used as an alternative therapy 
[42, 46]. However, there is still controversy regarding the role of ERβ in breast cancer and 
more studies in vivo need to be carried out [59]. Recently, we found that the pro-apoptotic 
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effect of ERβ both in mammary non-tumorigenic and breast cancer cells is reverted by 
activation of EGFR (Cotrim Z, in preparation). This suggests that cooperation of ERβ and 
EGFR pathways increase survival and growth, suggesting that the cellular context regulates 
ERβ activity.  
 
 
5. EGF/EGFR signalling  
 
The ErbB family of receptor tyrosine kinases is composed of 4 distinct members, 
EGFR (or HER1), HER2, HER3 and HER4. The four proteins present an extracellular 
ligand-binding domain, a transmembrane region and an intracellular tyrosine Kinase-
containing domain [17, 60]. The intracellular domain is highly conserved within the 
receptors (except HER3), but the extracellular ligand-binding domain is less conserved 
between the receptors, suggesting that they have different affinity for different ligands [61-
62]. 
  EGFR can be activated by a variety of ligands, such as EGF, transforming growth 
factor α (TGFα), Areg, heparin-binding EGF, or betacellulin [63-64]. Upon ligand binding, 
receptor homo or heterodimerization occurs followed by internalization and subsequent 
autophosphorylation of tyrosine kinase domain that serves as binding site for the 
recruitment of signal transducers and other molecules. This activation, in turn, triggers 
several downstream signalling such as phospholipase C-γ (PLCγ), Ras-Raf MAP Kinase, 
STAT and PI3 kinase – Akt pathways (Fig. 8) [62-64]. 
Several studies have demonstrated that ErbB family members are important for the 
development of many organs such as central nervous system, mammary gland, lungs or 
heart [65-67], since it regulate multiple biologic processes, such as gene expression, 
cellular proliferation, angiogenesis, and inhibition of apoptosis [63-64]. Activation of 
EGFR was also shown to promote tumour development, motility, adhesion and metastasis 
[68-69] and HER2 is overexpressed in approximately 30% of breast cancers and is 
associated with poor prognosis [70].  In addition, activation of MAP kinase and PI3 kinase 
pathways leads to ERα ligand independent activation [71]. 
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Figure 8– Signalling network dependent of EGFR activation. Source: Singh, A; 2005. 
 
 
6. Proteomic approach to breast cancer study 
 
Proteomics is the large-scale study of proteins using several techniques. These 
techniques allow the identification of proteins present in complex mixtures as is the case of 
the cell secretome. It also permits the study of protein-protein interactions and post-
translational modifications (PTM). In this manner it is possible to use a proteomic 
approach to identify biomolecular markers and better understand the molecular pathways 
that regulate cell differentiation and that if altered may lead to breast cancer initiation and 
progression [72-75]. Ultimately, this knowledge will allow earlier identification of the 
pathology and the development of new drugs and therapies. 
These studies can be performed with a variety of samples such as plasma, mammary 
gland tissue, nipple fluid or cell lines in culture. The results of these studies have 
demonstrated numerous differences on protein expression between tumorogenic and 
normal samples. Examples of relevant identifications are presented below.  
Within proteomic methodologies, we can distinguish between mass spectrometry-based 
tools (MS-based tools) and Non-based-MS tools. The Non-based-MS methodologies 
include mainly antibody reactivity requiring a previous biological knowledge of the 
proteins to be tested in bodily and tissue samples. On the other hand the MS-based 
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methodologies do not require this kind of knowledge permitting identification and 
characterization of a large number of proteins. Within MS-based approaches, and facing 
the advances in instrumentation, sample analysis can be performed by techniques 
catalogued in gel-based and non-gel based [73, 76].  
Gel-based proteomics include an initial separation step by gel electrophoresis (e.g. 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) or 2D-polyacrylamide gel 
electrophoresis (2D-PAGE)). For instance, in SDS-PAGE, the protein separation is done 
only by molecular weight, and in traditional 2D-PAGE proteins are separated in two 
dimensions being the first dimension related to the isoelectric point (pI) and the second 
dimension related to their molecular weight. Although 2D-PAGE allows a better protein 
separation and is the most used technique it has several disadvantages such as poor 
reproducibility, low sensitivity for identification of proteins in low concentrations and 
hydrophobic proteins and it is more expensive and time consuming than SDS-PAGE. 
However, the two dimensions allow separation of bands that in SDS-PAGE migrate 
together. After protein gel separation, bands/spots are cut from the gel, digested with a 
protease (typically trypsin) and peptides analysed by MS using peptide mass fingerprint. 
Matrix-assisted laser desorption ionization (MALDI-MS) and electrospray ionization (ESI-
MS) are the most common sources to analyse the digested peptides. These sources can be 
coupled to different types of analyzers such as time-of-flight (TOF) quadrupole, ion-trap. 
In peptide mass fingerprint, protein identification is obtained through the comparison of 
experimental mass-to-charge ratio (m/z) of the peptides with theoretical m/z of the peptides 
stored in databases. Identification can also be done by fragment mass fingerprint. In this 
case, tandem MS spectra is used to retrieve the best peptide sequence based on fragment 
ion for further comparison with theoretical m/z values existing in database [74, 77]. 
 
 
6.1. Matrix-Assisted Laser Desorption Ionization (MALDI) 
 
MALDI is a soft ionization technique utilized in MS, mainly for the analyses of 
biomolecules such as proteins, DNA or lipids. In this technique the sample is first 
dissolved in a suitable solvent and then co-crystallized with an appropriate matrix being 
spotted on a MALDI plate and air-dried or dried by nitrogen gas. The plate is put on the 
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spectrometer where a laser beam (typically a nitrogen laser) hits the co-crystallized sample 
leading to absorption of the laser energy by the matrix and consequent desorption and 
ionization of the analytes in the sample, mainly as single charged species (Fig. 10).  
 
 
 
Figure 9 - MALDI ionization process. Source: El-Aneed, A.; Cohen, A.; Banoub, J. 2009. 
 
 
Although, in the beginning MALDI was operated under vacuum it is now possible to 
operate at atmospheric pressure (AP) MALDI, reducing the cost of this technology and 
being easier to operate. The choice of the matrix depends not only on the sample to be 
analysed but also on the conditions under which the ionization is made. Normally, on the 
positive mode, acid matrices are used and on negative mode basic matrices are used [78-
81].      
 
 
6.2. Time of Flight (TOF) Analyzer 
 
In a second step, ions enter a TOF analyzer and the m/z is calculated based on the time 
the ionized ion takes to travel along the tube (variable length) until it reaches the detector. 
The principle is that if two ions are created at the same time, have the same charge and are 
accelerated with the same energy but have different weights, the lighter ion will reach the 
detector earlier. So, the m/z is inversely proportional to the time of flight.   
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Figure 10 - Scheme of a conventional TOF analyzer (A) and a TOF with reflectron (B).  
Source: El-Aneed, A.; Cohen, A.; Banoub, J. 2009. 
 
 
Comparing this kind of analyzer with others it has several advantages: all formed ions 
reach the detector and a very high mass range can be detected. However, the ions that enter 
the TOF have different kinetic energies affecting resolution and ion m/z measurement. To 
overcome this obstacle a reflectron (electrostatic ion mirror) was created. In a reflectron-
TOF ions with higher kinetic energies penetrate deeper on the mirror and are expelled on a 
higher velocity, improving resolution (Fig. 11). As this factor increases the path ions 
perform, it also permits more accurate m/z measurements. This kind of analyzer is also 
capable of tandem MS (MS/MS) [82-84].  
 
 
6.3. Tandem Mass Spectrometry (MS/MS) 
 
Although first order spectrums permit obtaining of rigorous m/z measures of the 
fragmented ions, they give little information about molecular structure and most frequent 
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and favourable molecular fragmentation. Thus, the protein identification is more reliable if 
done from a MS/MS spectrum since it allows almost complete peptide sequencing.    
On tandem mass spectrometry (MS/MS) the selected fragmented ions obtained in the 
first mass analyzer (MS1) are isolated and subjected to a posterior fragmentation through 
collision (normally with a gas) in a collision cell, being separated in a second analyzer 
(MS2) before reaching the detector (Fig. 12). 
 
 
 
Figure 11 – Representative scheme of tandem mass spectrometry (MS/MS). 
Source: El-Aneed, A.; Cohen, A.; Banoub, J. 2009. 
 
 
This type of analyzes can be made recurring to devices such as quadrupoles and TOF. 
MS/MS enhanced with these analyzers is called tandem-in-space because the analysis is 
performed by different mass analyzers. On the other hand, in tandem-in-time all ions are 
expelled from the trapping instrument except the selected ion. Within these instruments we 
can refer ITQ and FT-MS that can perform multiple MS experiments [85-87]. 
 
 
6.4. HC11 cells 
 
HC11 cell line has been widely used to model mammary epithelial differentiation. This 
cell line was obtained from the mammary gland of BALB/c mice in the middle of 
pregnancy. HC11 cells retain progenitor cells characteristics as they can be induced to 
differentiate (express milk proteins) in vitro [88] and can originate ductal and alveolar 
structures when implanted in vivo [89]. Comparison of the transcriptome of 
undifferentiated stage of HC11 cells to public breast cancer cell data showed that they 
share expression of markers with other stem cells and basal-like breast cancer cells [90]. 
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Since we do not exactly know if HC11 cells are “pure” stem cells or progenitor cells, we 
refer to them as stem cell like (SCL). HC11 cells are routinely kept in the undifferentiated, 
self-renewal and pluripotency stage by addition of EGF and induced to differentiate by 
withdrawal of EGF and addition of lactogenic hormones (dexamethasone and prolactin). 
For these reasons HC11 cell line presents several properties specific of normal mammary 
gland function, making them a relevant model to study markers and pathways in mammary 
gland development. A Schematic representation of the differentiation protocol of HC11 
cells is presented in Fig. 9. 
 
 
Figure 12 – HC11 cell differentiation program. A) Culture conditions used to achieve each differentiation stage. 
B) Expression of stem-cell like marker (Melk) and differentiation marker (beta-casein) achieved under the indicated 
growth conditions. Source: adapted from Williams, 2009 and Aydogdu (upublished). 
 
 
 
 
 
A) 
B) 
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7. Aim 
 
Paracrine and autocrine signalling play important roles in mammary epithelial cell 
proliferation, differentiation and apoptosis. Current knowledge supports the idea that breast 
cancer is the result of genetic or epigenetic alterations in mammary stem or progenitor cells 
[91] which remain quiescent until induced to expand. Further, breast cancer was the first 
tissue from which a tumour initiating cell subpopulation was identified [92]. Long-term 
exposure to estrogens and activation of ERα has been associated to breast cancer 
development [55]. However, little is known about how ERβ activation influences 
differentiation and cancer development, but current knowledge indicates it has a role in 
regulating adhesion.   
The main goal of this work was to identify novel secreted proteins which may serve as 
markers for different cellular states and provides a starting point for identification of novel 
pathways that regulate differentiation and that may become altered in breast cancer. It is 
also our objective to analyze the effect of ERβ ligand activation in the secretome of SCL 
cells and differentiated cells and identify possible mechanisms regulated by ERβ.  
 
Therefore, this work was divided into three specific aims: 
 
1. To use gel based MS to identify expression of secreted proteins in mammary 
epithelial cells throughout their differentiation program. 
2. To use gel based MS to identify expression of secreted proteins in undifferentiated 
(SCL) mammary epithelial cells under ERβ stimulation.  
3. To use gel based MS to identify expression of secreted proteins in differentiated 
mammary epithelial cells under ERβ stimulation. 
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II - Materials and Methods  
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In order to simplify the text reading, all solutions recipes used on the experimental 
approach can be consulted in annexe 2. 
 
Cell culture  
 
HC11 cells were routinely grown in complete medium. Collection of conditioned 
medium (CM) corresponding to each differentiation stage was done as follows. Actively 
proliferating, stem cell like (SCL) stage: once cells reached 60-70% confluence the 
medium was changed to SFM medium + EGF and after 24h incubation, the CM was 
collected. Pre-differentiated (-EGF 48h) stage: once cells reached confluence the medium 
was changed to pre-differentiation medium for 24h. Next, medium was changed for SFM – 
EGF and cells incubated for 24h more before the CM was collected. Differentiated (Dif) 
stage: once cells reached confluence the medium was changed to pre-differentiation 
medium for 48h. Then, medium was changed for differentiation medium and cells 
incubated for 48h. Next, medium was changed for SFM –EGF with addition of prolactin 
and dexamethasone and CM was collected after 24h. When ER ligand DPN was used, it 
was added to the indicated SFM for each differentiation stage and cells were incubated for 
24h before CM was collected.  
 
Protein precipitation and quantification 
 
The collected CM was centrifuged at 10000g for 15 min at 4ºC to remove cellular 
debris. Protein precipitation was carried out using the trichloroacetic acid (TCA) /acetone 
method. Briefly, the samples were incubated 2h at 4ºC with 1/10 acetic acid and 1/10 TCA 
100%. After the incubation, samples were centrifuged 15 min, 18000g, 4ºC. The resulting 
pellet was washed with ice cold acetone and subjected to a new centrifugation cycle after 
which the pellet was solubilised in solution 1 and proteins separated by SDS-PAGE. 
Pellets corresponding to samples resolved by 2D electrophoresis were solubilised in 
solution 2.   
Protein quantification was performed using the DC assay or RC/DC assay (BioRad) for 
samples solubilised in solution 1 or solution 2 , respectively.  
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SDS-PAGE 
 
Protein separation in a Tris-Glicine SDS-PAGE system was based on the protocol 
developed by Laemmli (1970) [93] where 10% and 6.25% gels were used. Equal amount 
of protein was used (20-30μg, depending on the gel). Proteins were solubilised with 1Vol 
of Laemmli loading buffer 5X every 4Vol of sample and proteins were denaturalized by 
boiling at 100ºC for 5 min. Then, samples were loaded in the gel and separated with 200V 
for 1h. The electrophoresis was ended once the front of the run reached the end of the gel.   
 
 
2D electrophoresis  
 
The samples separated by 2D electrophoresis were adjusted with rehydration buffer to a 
final volume of 250μl. Then, samples were placed in the holders and the 13cm 3-10 NL pH 
gradient Drystrips were laid on the top of the sample with the gel side down. The strips 
were covered with Drystrip cover fluid and the holders were placed on the IPG strip 
rehydrating chamber. Rehydration was carried out overnight (16.5h) at 20ºC at 50mA. 
After isoelectric focusing (IEF), the excess of Drystrip cover fluid was removed and the 
strips were equilibrated for SDS-PAGE in 2.5ml of equilibrium buffer for 15 min with 
gentle agitation. The strips were washed with running buffer and placed in top of a 10% 
gel. Agar solution was applied on top of the strips to seal the junction and to make a well 
for the molecular weight marker. SDS-PAGE was carried out at 200V, 20ºC until 
bromophenol blue reaches the bottom of the gel.   
 
 
Gel staining with Colloidal Coomassie (G250)  
 
After protein separation (SDS-PAGE or 2D electrophoresis) proteins were fixed for 1h 
in fixing solution. Next they were rinsed overnight in Colloidal Coomassie. Following 
staining, the gels were placed in distaining solution, till background noise was removed. 
Gel images were acquired on Molecular Imager Gel Doc XR+ System (BioRad) and 
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analysed with QuantityOne version 4.6.3 (BioRad) in the case of 1D gels or PDQuest 
version 8.0.1 (BioRad) for 2D gels.   
 
 
Protein identification 
 
Bands/spots of interest were cut from the gel and rinsed in 50μl Buf1 for 30 min, then 
50μl of ACN was added for additional 30 min, after which, it was also removed. These two 
steps were performed twice. The bands/spots were, once again, rinsed in 50μl ACN for 10 
min. Next, the bands/spots were incubated with trypsin, overnight at 37ºC. The 
supernatants were collected and storage and the digests were rinsed with formic acid for 30 
min and two times with a 1:1 solution of FA and ACN. All the supernatants were collected 
and evaporated in a SpeedVac and ressuspended in 10μl 50% ACN, 0.1% FA. Next, 0.5μl 
of the peptide mixture was spotted on the MALDI plate and covered with a 50% ACN, 
0.1% TFA acid and 5mg/ml α-cyano-4-hydroxycinnamic acid.  
The spots where analysed by MALDI-TOF, where the MS was performed with 900 
shots randomly distributed while in MS/MS was acquired 6 peaks with S-N˃30. Peptide 
masses obtained were exported using GPS software (v.2.0 Applied Biosystems) for 
searching the peptide mass fingerprints and MS/MS data. Searches were performed against 
the SwissProt (11/01/11) under rodentia, as taxonomic category and the following 
parameters: (i) two missed cleavages by trypsin; (ii) mass tolerance of precursor ions 
25ppm and product ions 0.3Da; (iii) carboxymethylated cysteines fixed modification; and 
(iv) oxidation of methionine as variable modification. 
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III – Results and Discussion 
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1. Proteins indentified in the mammary epithelial cell secretome throughout the 
differentiation program.  
 
Differentiation of mammary epithelial cells is dependent on autocrine and paracrine 
signalling. With the goal of better understanding these mechanisms, HC11 cells were 
cultured to obtain three stages of mammary epithelial cell differentiation:  
a) Stem-cell like (SCL), when cells are capable of self-renewal and pluripotency (it was 
obtained by culturing with EGF (+EGF));  
b) Pre-differentiation (PD) stage, when cells enter the differentiation process but the 
process can be partially reversed (it was obtained by withdrawal of EGF (-EGF for 24-
48h));  
c) Differentiation (D) stage, when cells express milk proteins (+Prl + Dex -EGF).  
To better understand the protein profile of mammary epithelial cells as they transit the 
differentiation program, conditioned media (CM) of SCL, PD and D stages was analyzed 
using a gel based MS approach. The first step was to analyze the proteins in the CM of 
each differentiation stage using SDS-PAGE. A representative image of a SDS-PAGE 
(10%) showing a comparison between the protein profiles of the 3 conditions, SCL, PD 
and D is shown in Fig. 14. All bands were cut and identified by MALDI-TOF/TOF and 
presented in Table 1. Those bands differentially detected are indicated with numbers which 
are also referred to in Table 1. 
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Figure 13 – SDS gel comparing protein profile between SCL, PD and D. 
The numbers indicate proteins differentially identified.  
Identifications are reported in Table 1. 
 
Some tecnhical dificulties were encountered using SDS-PAGE such as contamination 
with serum albumin due to the high concentration levels even in the absence of bovine 
fetal serum. In addition, some of the proteins have similar molecular weight impossibiliting 
their identification and there was a high number of proteins present in the sample that due 
to their lower concentration were not possible to identify.  
So, the next step was to perform a 2D-PAGE separation to try to overcome some of the 
dificulties presented to us when using SDS-PAGE. The protein profiles of the 3 conditions 
are shown in Fig. 14 and the proteins identified are also listed in Table 1. 
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Figure 14 – 2D-PAGE comparing protein profile between A) SCL, B) PD and C) D. 
The numbers indicate proteins differentially identified. Identifications are reported in Table 1 
 
A total of 75 (SCL), 123 (PD) and 80 (D) positive identifications were obtained by 1D 
and 2D. Since this work pretends to study the secretome of cells in each stage, we only 
analyzed proteins that are known to be extracellular or are present in the membrane or 
lysosome/exosome compartments. However, tables with all proteins identified are 
presented in the annexes section. The number of secreted or potentially extracellular 
proteins was 20 (SCL), 28 (PD) and 24 (D).  
A combined identification by SDS-PAGE or 2D-PAGE permitted the identification of a 
total of 40 different proteins within the 3 classes. Table 1 shows the proteins secreted in the 
3 experimental conditions giving also information about the accession number, protein 
MW, pI and peptide count. In addition, Fig. 15, shows a Venn diagram for easier 
visualisation of the results. 
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Table 1 – Proteins identified from the secretome of mammary epithelial cells with a C.I.%˃95%.  
# SCL PD D Protein name (gene name) 
Acession 
number 
Protein 
MW (Da) 
Protein 
pI 
Peptide 
count 
21  X  14-3-3 protein sigma (Sfn) O70456 27696 4,75 8 
22 X X  
6-phosphogluconate 
dehydrogenase, decarboxylating 
(Pgd) 
Q9DCD0 53213 6,81 3 
17 X X X Alpha-enolase (Eno1) P17182 47111 6,37 9 
20 X  X Annexin A2 (Anxa2) P07356 38652 7,55 15 
12 X X  Annexin A3 (Anxa3) O35639 36349 5,33 11 
   X Annexin A5 (Anxa5) P48036 35730 4,83 19 
  X  Annexin A8 (Anxa8) O35640 36820 5,56 2 
23  X  
Basement membrane-specific 
heparan sulfate proteoglycan core 
protein (Hspg2) 
Q05793 398039 5,88 2 
   X Cadherin-1 (Cdh1) P09803 98195 4,69 5 
14  X X Calreticulin (Calr) P14211 47965 4,33 16 
6  X  Calsyntenin-1 (Clstn1) Q9EPL2 108831 4,82 11 
   X Carboxypeptidase E (Cpe) Q00493 53222 5,07 10 
26  X X Cathepsin D (Ctsd) P18242 44925 6,71 7 
8 X X X Ceruloplasmin (Cp) Q61147 121074 5,53 16 
 X   Coagulation factor VIII (F8) Q06194 265981 6,9 17 
7  X X Collagen alpha-1(II) chain (Col2a1) P28481 141886 6,58 32 
18 X   
Collagen alpha-1(VI) chain 
(Col6a1) 
Q04857 108422 5,2 9 
  X  
Collagen alpha-1(XI) chain 
(Col11a1) 
Q61245 180853 5,09 7 
9 X X X Complement C3 (C3) P01027 186365 6,39 22 
27   X 
Connective tissue growth factor 
(Ctgf) 
P29268 37768 8,22 2 
  X  Cystatin-C (Cst3) P21460 15521 9,18 9 
   X 
EF-hand domain-containing protein 
D2 (Efhd2) 
Q9D8Y0 26775 5,01 9 
 X X  
Extracellular superoxide dismutase 
[Cu-Zn] (Sod3) 
O09164 27375 6,36 3 
24 X X  Fascin (Fscn1) P85845 54457 6,29 3 
1 X X X Fibronectin (Fn1) P11276 272319 5,39 35 
13 X X X Galectin-3 (Lgals3) P16110 27498 8,46 6 
10  X X 
Insulin-like growth factor-binding 
protein 5 (Igfbp5) 
Q07079 30353 8,48 5 
19  X  Liprin-alpha-3 (Ppfia3) P60469 116208 5,72 4 
15  X  
Metalloproteinase inhibitor 2 
(Timp2) 
P25785 24312 7,45 5 
11 X X X 
Neutrophil gelatinase-associated 
lipocalin (Lcn2) 
P11672 22861 8,96 6 
3 X X X Periostin (Postn) Q62009 93085 7,27 25 
   X 
Prostate and testis expressed 
protein 3 (Pate3) 
B3GLJ3 11652 9,14 5 
4 X X X Protein disulfide-isomerase (P4hb) P09103 57108 4,79 18 
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 X X  
Protein disulfide-isomerase A3 
(Pdia3) 
P27773 56643 5,88 5 
 X X X 
Protein disulfide-isomerase A6 
(Pdia6) 
Q922R8 48143 5 6 
   X Renin receptor (Atp6ap2) Q9CYN9 39067 5,36 6 
25 X X  Serpin B5 (Serpinb5) P70124 42085 5,55 7 
16 X X X Serum albumin (Alb) P07724 68648 5,75 8 
5 X X X SPARC (Sparc) P07214 34428 4,77 11 
2 X  X Thrombospondin-1 (Thbs1) P35441 129564 4,72 11 
#: numbers presented in the gel images. 
X: identified in the indicated stage. 
OBS: Some identifications are not shown in the represented gels but were presented in others.  
 
Eleven proteins were detected in all differentiation stages: Alpha-enolase, 
Ceruloplasmin, Complement C3, Fibronectin, Galectin-3, Neutrophil gelatinase-associated 
Lipocalin, Periostin, Protein disulfide-isomerase, Protein disulfide-isomerase A6, Serum 
Albumin and SPARC. Other proteins were only detected in 1 of the classes. Coagulation 
factor VIII and Collagen alpha-1(VI) chain were only identified in SCL stage. Twelve 
proteins were identified when cells entered the differentiation program (-EGF): 14-3-3 
protein sigma, Anexin A8, Calreticulin, Calsystenin, Cathepsin D, Collagen alpha 1 (II and 
XI) chains, Cystatin-C,  Basement membrane-specific heparan sulfate proteoglycan core 
protein, Insulin-like growth factor-binding protein 5, Liprin-alpha-3 and Metalloproteinase 
inhibitor 2. Since entering the differentiation program is induced by withdrawal of EGF, it 
is likely that this growth factor either regulates transcription, stability and/or secretion of 
the above listed proteins.  
Functional differentiation induced by addition of Prol and Dex resulted in identification 
of 7 proteins characteristic of D stage: Anexin A5, Cadherin 1, Carboxypeptidase E, 
connective tissue growth factor, EF-hand domain-containing protein D2, Prostate and testis 
expressed protein 3 and Renin receptor. Unfortunately, due to technical problems, all spots 
present in D stage could not be analyzed. Therefore, proteins present in SCL and PD but 
not identified in D cannot be considered as differentially regulated in our analysis and 
more than the seven listed proteins may be characteristic of D stage. 
Previously, it was shown that Insulin-like growth factor-binding protein 5 is expressed 
in differentiated HC11 cells [94]. In this analysis, Insulin-like growth factor-binding 
protein 5 was found in lower levels in SCL stage compared to D stage. In addition 
ceruloplasmin as well as complement C3 which were both upregulated in D (Table 3) have 
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been identified in breast milk [95-96]. Thus, indicating that in these experimental 
conditions, HC11 cells recapitulate the mammary epithelial cell differentiation program.  
A previous transcriptomic study [90] showed different expression patterns in SCL 
comparatively to D stage. Several genes corresponding to proteins identified in this work, 
were found underexpressed in D when compared to SCL including Thrombospondin-1, 
Annexin A8 and Fascin. On the contrary, Cathepsin D, Collagen alpha-1(II) chain and 
Ceruloplasmin were upregulated.  
 
 
Figure 15– Venn diagram of the identified proteins and their distribution. 
 
With information gathered from the proteins identified in each condition, pie charts 
with biological processes were built (Fig.16). It is possible to observe that the 3 top 
represented biological processes were the same in all the conditions: Cell communication 
(52,6% in SCL; 46,4% in PD; 42,9% in D), cell adhesion (30,0% in SCL; 33,3% in PD; 
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25,0% in D) and metabolic process (63,2% in SCL; 57,1% in PD; 39,3% in D). Another 
important biological process is transport, which was represented by 42,1% in SCL; 32,1% 
in PD and 25,0% in D. On the bottom down, apoptosis (1,3% in SCL; 1,1% in PD; 1,2% in 
D) was one of the less represented biological process as well as cell cycle (1,1% in PD; 
2,4% in D) which was represented in PD and D conditions and not present in SCL.  
 
 
 
Figure 16– Pie charts with Biological processes of identified proteins A) SCL B) Pre-differentiated  
C) Differentiated 
 
Information about molecular function of the proteins present in each condition was also 
analysed. The most represented functions were: binding (63% in SCL, 57% in PD; 54% in 
D) and Catalytic activity (42% in SCL, 29% in PD; 25% in D).      
Relatively to the protein classes identified and according to Pantherdb.org database, we 
could identify 2 major classes in the 3 conditions (Table 2): signalling molecules (42,1% in 
SCL; 21,4% in PD; 25,0% in D) and transfer/carrier proteins (21,1% in SCL; 14,3% in PD; 
14,3% in D).  
A 
B C 
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Table 2 – Proteins belonging to the 2 major proteins classes. 
Protein class Proteins identified 
signalling molecules Ctgf; C3; Col6a1; Fn1; Lgals3; F8; Col11a1; Postn; Thbs1; Sparc 
transfer/carrier 
proteins  
Anxa8; Lcn2; Anxa2; Anxa3; Anxa5; Alb 
 
Several metabolic pathways were identified; however, most of them were only 
represented by 1 protein. Integrin signalling pathway is the only one that in the 3 
conditions showed more than 1 protein identified. Since levels of Collagen type VI, II, XI 
and Fibronectin activate different integrin dimmers and the levels of these ECM proteins 
varied between the differentiation stages. This finding is in agreement with the idea that 
integrin signalling regulates cell differentiation [97]. In SCL stage, 2 proteins participate in 
p53 pathway: Thrombospondin-1 and Serpin B5, which are upregulated by p53 and in turn, 
inhibit migration and angiogenesis [98-100].  
 
The intensity of the bands/spots separeted by 1D or 2D-PAGE was measured and 
normalized, permiting a comparison between the 3 conditions. On table 3, the proteins that 
are only over or under represented in SCL or PD compared to D stage are shown. This 
should allow us to have a better understanding of the process of differentiation.   
 
Table 3 – Protein variation on SCL and PD when compared to D stage.  
Protein name Variation 
(mean±SD) 
Protein name Variation 
(mean±SD) 
Up only in SCL 
Thrombospondin-1  1,68±0,40 Protein disulfide-isomerase  1,81±0,40 
Alpha-enolase 1,60±0,10 Fibronectin  2,87±0,20 
SPARC  1,23±0,03   
Up only in PD 
Insulin-like growth factor-binding 
protein 5 
1,31±0,06   
Down only in SCL 
    
Down only in PD 
Periostin   0,51±0,16 Collagen alpha-1(II) chain 0,13±0,08 
Ceruloplasmin 0,48±0,25 Complement C3 0,16±0,03 
Neutrophil gelatinase-associated 
lipocalin 
0,05±0,57   
 
Comparing SCL with PD and D we found 5 upregulated proteins and 1 protein that was 
only detected in SCL (Table 1 and 3). Five of the upregulated proteins are involved in cell 
communication: Thrombospondin-1, Fibronectin, Collagen type VI, Coagulation factor 
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VIII and SPARC. They act as receptor ligands and are able to modulate cell-cell or cell-
matrix adhesion. Thrombospondin-1 is also implicated in inhibition of angiogenesis and 
tumour growth as well as regulation of MMP-9 (facilitates angiogenesis and tumour 
invasion) activity an activation of vascular endothelial growth factor (VEGF) signalling 
[101-102]. In addition, SPARC was also found in higher levels in SCL compared to PD 
and D. SPARC is a glycoprotein that interacts with ECM proteins to promote cell adhesion 
to the matrix. It also plays an important role in tissue remodelling, angiogenesis and 
tumorigenesis [103-105]. In breast cancer SPARC can promote invasion, motility and 
activity of matrix metalloproteinases [106]. SPARC is overexpressed in breast tumour 
tissues when compared to normal breast tissues and is also highly expressed in aggressive 
breast cancer cell lines [75, 107]. Fibronectin is capable of modulating cell motility, 
adhesion and shape and is thought to inhibit angiogenesis, tumour growth and metastasis 
[108]. Thus, it seems that SCL cells have both pro-angiogenic/invasion factors (SPARC) as 
well as factors that counteract that activity (Thrombosponding and fibronectin) which may 
explain the regulated “normal” behaviour of these cells.  
Coagulation factor VIII was only identified in SCL stage. Interestingly, mammary 
glands from transgenic rabbits expressing human recombinant Coagulation factor VIII 
showed decreased levels of apoptosis and higher number of mitochondria [109], indicative 
of a pro-survival effect as well as higher metabolism exerted in SCL stage by this factor.  
Protein disulfide-isomerase and alpha-enolase were also upregulated in SCL being the 
second involved in glicolysis and is thought to participate in growth control and tolerance 
to hypoxia [75]. Alpha-enolase was found overexpressed in breast cancer [110].  
Calreticulin, Cathepsin D and Insulin-like growth factor-binding protein 5 were 
identified in PD and D but not in SCL. Insulin-like growth factor-binding protein 5 has 
been shown to inhibit the growth promoting effects of the IGF growth factor family on cell 
culture and promote apoptosis [111-112], Calreticulin is a Ca
2+
 - binding chaperone that 
promotes the folding of synthesized proteins [113] and is thought to affect Fibronectin 
production and, hence, cell adhesion [114]. It was pointed as a possible prostate and 
bladder cancer biomarker [115-116].  
Therefore, it seems that when cells enter the differentiation program, a reduction of 
Fibronectin levels may be related to higher levels of Calreticulin.  
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Cathepsin D is involved in enzymatic degradation in lysosomes and also activates some 
proteins precursors in specialized cells [117-118]. Using mass spectrometry this protein 
was found to be more abundant in aggressive tumours stimulating metastasis and 
promoting angiogenesis [75]. It also induces fibroblasts to produce extracellular matrix 
proteases [119-120]. Elevated Cathepsin D levels are correlated with higher incidence of 
metastasis and lower survival rates [121-122]. However, this lysosomal aspartic protease is 
present in mammary tissue and milk in various molecular forms and is secreted in an active 
form by Prl stimulation [123], is itself involved in cleavage of basally located Prl [124] and 
its activity is inhibited by Serpin B5 [125]. This is an interesting observation, since in the 
secretome of HC11 cell differentiation program Cathepsin D is not present in SCL stage, 
when Serpin B5 is found in higher levels, they are both present when cells begin to 
differentiate (PD) and only Cathepsin D is found in D stage, when the action of Prl would 
be needed. 
 Several proteins were found only in D stage: Annexin A5, Cadherin-1, 
Carboxypeptidase E, Connective tissue growth factor, EF-hand domain-containing protein 
D2, Prostate and testis expressed protein 3 and Renin receptor. Of these proteins, 
Cadherin-1 is involved in mechanisms regulating cell-cell adhesion, mobility and 
proliferation of epithelial cells and has a potent invasion suppressor role [126-127]. 
However, E-cadherin is a transmembrane protein which is prone to extracellular protease 
cleavage, a mechanism used by cancer cells to promote migration. Since this is not likely 
to occur in D stage, and E-cadherin is highly expressed in this stage [90], one possibility is 
that protein fragments resulted from apoptotic bodies present in the CM. Connective tissue 
growth factor mediates cell adhesion, is the most upregulated gene in HC11 D stage [90] 
and was recently identified as upregulated by Dex and highly expressed in pregnant and 
lactating mouse mammary glands [128]. Connective Tissue Growth Factor can function 
both as growth factor and, if associated to ECM, as cell adhesion molecule blocking 
anoikis [129]. EF-hand domain-containing protein D2 is capable of regulating apoptosis 
through BCL2L1 expression [130].  
Besides the mentioned proteins, D condition presented an upregulation of Complement 
C3, Ceruloplasmin, Collagen alpha-1(II) chain and Neutrophil gelatinase-associated 
lipocalin. It has been proposed that Ceruloplasmin transports iron into malignant cells and 
it is upregulated in human breast cancer cell lines, but also in milk [131-132]. Although the 
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exact function of Neutrophil gelatinase-associated lipocalin is not yet established, some 
authors consider that it could be involved in protecting MMP-9 from degradation, 
enhancing its enzymatic activity and facilitating angiogenesis and tumor growth [133-134] 
or that it could be correlated with apoptosis and cell survival [135]. Further, Neutrophil 
gelatinase-associated lipocalin has been identified in bovine colostrum [136] and is also 
expressed in lumen of ducts close to breast carcinomas (a sign it is secreted) it is associated 
to poor prognosis [137] and may be a transporter and survival factor [135]. Interestingly, 
and similar to these findings, well- to moderately differentiated pancreas cancer  (PaCa) 
cells express high levels of Neutrophil gelatinase-associated lipocalin but moderately to 
poorly differentiated PaCa cells express undetectable levels of this protein which may have 
a role as suppressor of invasion in PaCa cells [138]. 
Therefore, factors found in CM from D contribute to inhibition of invasion and 
survival. 
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2. Protein expression in undifferentiated mammary epithelial cells under 
estrogenic stimulation with or without EGFR activation. 
 
Estrogen receptors are widely expressed in the mammary gland. ERα is majorly 
detected in ductal epithelial cells and its expression is reduced as cells differentiate during 
pregnancy and lactation. On the other hand, ERβ expression is maintained constant 
throughout the reproductive cycle [11]. The mammary response to estrogens is also 
variable throughout the reproductive cycle. Estrogens (through ERα), induce proliferation 
in puberty but in the pregnant mammary gland, E2 does not induce more proliferation or 
expression of E2 regulated genes such as PR [5, 139], indicating that in this reproductive 
stage, the mammary gland is not responsive to E2. On the other hand, ERβ has been shown 
to positively influence cell differentiation, especially during lactation [6]. Differential 
response to estrogens as well as the fact that even if cells express ERs, not all cells respond 
in the same way, may be due to activation of signalling pathways such as MAP kinase and 
PI3-kinase that influence the differentiation stage but also ER transcriptional activity.  
Mammary stem and progenitor cells appear to be the most likely target of carcinogens, 
and long term estrogen exposure has a carcinogenic effect on the mammary epithelium. In 
this context, it could be of particular interest because the EGF/EGFR pathway is known to 
promote ERα transcriptional activity [12, 140] and proliferation of the mammary 
epithelium and is needed for maintenance of SCL phenotype. There is no information 
regarding the effect of EGF on endogenous ERβ. However, EGF can also stimulate 
transcription of overexpressed ERβ. Since ERβ was shown to regulate apoptosis, cell 
adhesion, migration and inhibit proliferation [6, 58] and is expressed throughout the whole 
reproductive cycle of the mammary gland, a detailed study of how EGF/EGFR signalling 
affects ERβ function is needed.  
Therefore, this part of the study will compare the secretome of SCL cells (+EGF) and 
SCL cells as they begin the differentiation program (-EGF), when treated with the ERβ 
agonist DPN. For this purpose, we used a similar experimental approach as outlined in 
section 1. First, proteins form the CM were separated in a SDS-PAGE (10%) and secondly 
in a 2D-PAGE. Then bands/spots were cut, digested and analyzed by MALDI-
TOF/MS/MS. Analysis was carried out only with proteins that are either secreted or can 
potentially be found in the extracellular space. 
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Fig. 17 shows the protein profile from SCL +EGF and -EGF cells simultaneously 
treated with DPN for 24h.  
 
 
Figure 17 – SDS gel comparing protein profile between SCL +EGF (CTR and DPN) and -EGF (CTR and DPN).  
              The numbers indicate some of the identified proteins which are reported in Table 1.   
 
A 2D-PAGE separation was carried out with the 4 conditions mentioned above and the 
result is presented in Fig. 18. A larger number of spots were detected in the -EGF condition 
when compared to +EGF condition (panels C versus A, respectively). A similar 
observation was made when the same samples were separated by SDS-PAGE (annexe 2).  
However, when density of all bands was calculated, we observed no difference which 
indicates that there was no error in protein quantification. 
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Figure 18 - 2D gel comparing protein profile between SCL cells  A) +EGF CTR; B) +EGF DPN; C) –EGF CTR 
and D) –EGF DPN. Identifications are indicated by the numbers and are reported in Table 1.  
 
 
The density values of the bands/spots were measured and the variation for each one 
was calculated and presented in Table 4. 
A total of fifteen proteins were found regulated by DPN. Independently of EGF 
presence: DPN upregulated Ceruloplasmin, Extracellular superoxide dismutase [Cu-Zn], 
Protein disulfide-isomerase and Protein disulfide-isomerase A6 as well as SPARC; while 
Protein disulfide-isomerase A3 was downregulated by DPN. Fibronectin was 
downregulated by DPN only in cells + EGF and Basement membrane-specific heparan 
sulfate proteoglycan core protein, Calreticulin, Calsystenin, Collagen alpha-1 (VI) chain 
and Alpha-enolase were upregulated by DPN in cells -EGF. 
Interestingly, Serpin B5 and Fascin were upregulated by DPN in cells +EGF, but 
downregulated in cells -EGF. On the other hand, Complement C3, Periostin, Galectin-3 
and Neutrophil gelatinase-associated Lipocalin were downregulated by DPN in cells 
+EGF, but upregulated in cells –EGF. 
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Table 4 – Proteins up and downregulated in +EGF (CTR and DPN) and -EGF (CTR and DPN). 
Protein name 
Variation 
(mean±SD)
* 
Protein name 
Variation  
(mean±SD)
* 
Up in +EGF DPN compared to +EGF CTR 
Ceruloplasmin 1,52 Protein disulfide-isomerase 1,49±0,13 
Cystatin-C 1,13 Protein disulfide-isomerase A6 1,47 
SPARC 1,51 Serpin B5 1,60 
Fascin 1,18   
Down in +EGF DPN compared to -EGF CTR 
Complement C3 0,13 
Neutrophil gelatinase-associated 
lipocalin 
0,11 
Fibronectin 0,70±0,07 Periostin 0,82 
Galectin-3 0,56 Protein disulfide-isomerase A3 0,74 
Up in -EGF DPN compared to -EGF CTR 
Basement membrane-specific heparan 
sulfate proteoglycan core protein 
1,68 
Extracellular superoxide 
dismutase [Cu-Zn] 
1,24±0,13 
Calreticulin 1,56 Galectin-3 1,16 
Calsyntenin-1 1,41±0,06 
Neutrophil gelatinase-associated 
lipocalin 
1,53 
Ceruloplasmin 1,75 Periostin 1,65 
Collagen alpha-1(VI) chain 1,14±0,01 Protein disulfide-isomerase 1,29 
Complement C3 1,47 Protein disulfide-isomerase A6 1,12 
Alpha-enolase 1,21±0,05 SPARC 1,74 
Down in -EGF DPN compared to -EGF CTR 
6-phosphogluconate dehydrogenase, 
decarboxylating 
0,78 Protein disulfide-isomerase A3 0,83 
Fascin 0,75 Serpin B5 0,65 
*SD only if more than one measure was available. 
 
With the information from table 4, pie charts of biological processes were built (Fig. 
19). The most represented processes of proteins upregulated in +EGF DPN were metabolic 
process (83,3%) and cell communication (33,3%). Proteins downregulated in +EGF DPN 
besides participating in metabolic processes (50%) and cell communication (66,7%) are 
also involved in immune system response (66,7%) and cell adhesion (50%). Taking into 
account the molecular function of the proteins over or under regulated in +EGF DPN, the 3 
most represented functions were binding (61,5% in up and downregulated), catalytic 
activity (50% in up and 33,3% in downregulated) and enzyme regulator activity (50% in 
up and 16,7% in downregulated). When we separated the proteins according to their 
classes, we found that in +EGF +DPN condition, enzyme modulator (33,3%) and 
isomerase (33,3%) are the major classes of proteins in high levels, while proteins found in 
low levels in +EGF DPN are mostly signalling molecules (66,7%). 
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Proteins upregulated in -EGF condition treated with DPN participate in several 
processes such as metabolic processes (53,0% of the proteins), cell communication 
(53,0%) and cell adhesion (38,5%). Relatively to the molecular functions of those proteins 
the most represented are binding (61,5%) catalytic activity (38,5%) and enzyme regulator 
activity (15,4%). The proteins identified in high levels in –EGF DPN can be aggregated 
into classes being the most represented signalling molecules (38,5%) and isomerase 
(15,4%).    
Relatively to the proteins found in low levels in –EGF DPN we cannot make this type 
of discussion due to the low number of identifications.  
One interesting finding was the clear effect of DPN in the induction of developmental 
processes (Basement membrane-specific heparan sulfate proteoglycan core protein, 
Ceruloplasmin and Periostin) and apoptosis processes (Galectin-3) in SCL cells beginning 
to differentiate (-EGF). On the contrary, SCL cells +EGF with DPN treatment have shown 
reduced developmental process (only represented by ceruloplasmin) and absence of 
apoptosis. In addition, cell communication was more represented in –EGF+DPN 
(Complement C3, Basement membrane-specific heparan sulfate proteoglycan core protein, 
Ceruloplasmin, SPARC, Periostin and Neutrophil gelatinase-associated lipocalin) than in 
+EGF+DPN (only SPARC and Ceruloplasmin). When looking at the regulation of these 
proteins it is evident that those representing the above mentioned processes in -EGF+DPN 
are those proteins upregulated in this condition but downregulated in +EGF+DPN. 
Therefore, these results indicate that in HC11 cells, activation of ERβ will influence cell 
signalling differently depending on the differentiation stage of the cell. Further, it is 
evident that the tumor supressor role of ERβ occurs in cells on their way to differentiation 
and not in SCL cells, an observation suported by our unpublished data (Cotrim, Z in 
preparation).  
It was also the goal of this work to study the pathways in each the proteins found 
however, all the pathways identified were only represented by one protein. 
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Figure 19 - Pie charts with Biological processe of identified proteins A) Overexpressed in +EGF +DPN B) 
Underexpressed in +EGF +DPN C) Overexpressed in -EGF DPN and D) Underexpressed in -EGF DPN. 
 
Among proteins equally upregulated by DPN with or without EGF, Protein disulfide-
isomerase was shown to bind intracellular E2 and through its release to modulate ER 
activity. In addition, Protein disulfide-isomerase can physically interact with ER acting 
somewhat as a chaperone [141-142]. Therefore, it is possible that increased ERβ signalling 
requires higher levels of Protein disulfide-isomerase. In adition, 2D electrophoresis of 
bovine smooth muscle cells identified Pdia as downregulated by E2 [143] which indicates 
that ERs regulate Protein disulfide-isomerase levels. 
SOD3 has a role in protecting the cells from radical oxygen species (ROSs). E2 has a 
protective role on the endothelium and the beneficial effects of E2 in the circulatory system 
have been known for years [46]. In addition, ovariectomy of rats (depletion of endogenous 
E2) lead to SOD3 downregulation and increased oxidative stress, this effect can be 
reversed by administration of E2. Our results indicate that in the mammary epithelium, 
ERβ can protect from oxidative stress by induction of SOD3.  
A B 
C D 
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The extracellular matrix protein SPARC binds calcium, a co-factor needed for cadherin 
and integrin activation. Hence, SPARC regulates cell adhesion. Altered expression has 
been reported in breast cancer but the role of this potential tumour biomarker remains 
controversial. However, both Fibronectin and SPARC are present in an extracellular matrix 
cluster associated to good prognosis and disease free survival [144]. These results, indicate 
that in a non cancerous environment, activation of ERβ increases SPARC levels and may 
be one mechanism by which ERβ regulates cell adhesion.  
Fibronectin expression is also associated to good prognosis in breast cancer [144]. The 
fact that it is only regulated by DPN (down) in SCL cells with EGF supports our finding 
that the tumour suppressor role of ERβ is lost when cells are grown with EGF (Cotrim C, 
in preparation). 
Periostin, Galectin-3 and Neutrophil gelatinase-associated lipocalin were 
downregulated by DPN in cells +EGF and upregulated in cells –EGF. Periostin binds to 
heparin and seems to play a role in cell adhesion. It may also be involved in extracellular 
matrix mineralization [145-146]. Besides, Periostin mRNA was shown to be upregulated 
by ERβ in primary human periodontal ligament cells [147]. Galectin-3 is a lectin that is 
involved in normal and pathological processes. It may exhibit anti- or pro-apoptotic 
activity depending on the nature of the stimulus. [148]. Altered expression of galectin-3 
has been described in many cancers, and studies of cancer cell lines have implicated this 
lectin in various aspects of the tumorigenic cascade. However, galectin-3 is strongly up-
regulated during mammary gland involution [149] and may induce integrin beta1 
endocytosis [150].  
In summary, ERβ regulates expression of proteins involved in regulation of adhesion 
and apoptosis. However, since different regulation was observed in SCL (+EGF) cells 
compared to cells entering differentiation (-EGF), the cellular context seems to drive ER 
activity.  
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3. Protein expression in differentiated mammary epithelial cells with or without 
ERβ activation. 
 
Hormone treatment in lactating mammary glands (i.e. birth control pills in humans, E2 
treatment in cows) induces regression and reduced milk synthesis. This occurs through 
blockade of JAK/STAT5 signalling [151] and induction of cell death. Since mammary 
gland involution (regression) depends on detachment of alveolar cells from the ECM 
(anoikis) and during lactation ERβ regulates expression of several adhesion proteins, we 
aimed to study if ERβ influences secretion of factors which can modulate adhesion. To 
accomplish this goal differentiated cells were treated with DPN and the CM proteins 
separated in a SDS gel (10%) (Fig. 20).  
 
 
 
Figure 20- SDS gel comparing protein profile of differentiated cells with or without DPN. 
 Identifications report to table 1. 
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The density variations of all the secreted proteins found in differentiated cells were 
calculated and regulated proteins are shown in Table 6.  
 
DPN upregulated key proteins involved in mammary epithelial cell differentiation 
were: Connective tissue growth factor and Insulin-like growth factor-binding protein 5 as 
well as Cathepsin D, Collage alpha 1 (II) chain and Fibronectin, while it downregulated 
Neutrophil gelatinase-associated lipocalin. All these proteins clearly cluster within the 
extracellular matrix proteins which indicates that in the lactating epithelium, ERβ 
regulation of cell adhesion molecules like integrin alpha 6 and 2 as well as E-cadherin [30] 
may be a result of a complex regulation between, binding of these proteins to their 
substrate as well as protein stability. 
 
Table 5  – Proteins upregulated on differenciated cells with different treatments. 
Protein name 
Variation 
(Mean±SD)* 
Protein name 
Variation 
(Mean±SD)* 
Upregulated by DPN 
Cathepsin D 1,16 Fibronectin 1,33±0,17 
Collagen alpha-1(II) chain 1,24±0,13 
Insulin-like growth factor-binding 
protein 5 
1,31 
Connective tissue growth factor 1,35   
Downregulated by DPN 
Neutrophil gelatinase-associated 
lipocalin 
0,46   
*SD only if more than one measure was available. 
 
Finally, Complement C3, Periostin and SPARC, three proteins upregulated by DPN in 
cells entering differentiation (-EGF) (Table 4), were not regulated in D cells. Therefore, 
and even thought D cells are obtained in –EGF medium, these results clearly show that 
ERβ activity is regulated by the differentiation stage of the cell. 
 
 
 
 
 
 
 
50 
 
 
 
 
 
 
 
 
 
 
IV – Conclusion 
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With the goal to identify secreted proteins which can potentially regulate mammary 
epithelial cells as they transit the differentiation program, the secretome of SCL, PD and D 
stages was analyzed using a gel based MS approach. 
This analysis showed in SCL stage an increase of proteins such as SPARC, 
Coagulation factor VIII, Fibronectin, Thrombospondin-1 and Serpin B5. 
SPARC is known to promote angiogenesis and invasion in breast cancer [105], being 
highly expressed in more aggressive breast cancer cell lines [107]. Besides, Coagulation 
factor VIII was only identified in this condition and was showed to inhibit apoptosis and 
increase metabolism [109]. These facts suggest that in SCL condition, secreted proteins 
have pro-angiogenic/invasion as well as pro-survival roles. These mechanisms are 
important for the maintenance of the proliferative state of this condition. However, 
Fibronectin, Thrombospondin-1 and Serpin B5 were also found in higher levels. These 
proteins are thought to inhibit angiogenesis, invasion and tumour growth [98, 100]. In fact, 
both Thrombospondin-1 and Serpin B5 participate in p53 pathways, being upregulated by 
the tumour suppressor p53 and in turn, inhibit migration and angiogenesis.  
Thus, it seems that in SCL cells factors that enhance angiogenesis, invasion and inhibit 
apoptosis are co-secreted with factors that have the opposite effects. Is this crosstalk of 
signals that could explain the regulation of SCL state, that implicates a need to proliferate 
and migrate and at the same time the necessity to control these processes.  
 
When entering differentiation (-EGF), we encountered several proteins upregulated 
such as Insulin-like growth factor-binding protein 5, Calreticulin, Cathepsin D, Connective 
tissue growth factor and Neutrophil gelatinase-associated lipocalin.  
Insulin-like growth factor-binding protein 5 has been showed to inhibit the growth 
promoting effects of the IGF growth factor family on cell culture and promote apoptosis 
[111-112]. Calreticulin is thought to affect Fibronectin production and, hence, cell 
adhesion [114]. Although Cathepsin D was found to be more abundant in aggressive 
tumours stimulating metastasis and promoting angiogenesis it is also induced by Prl 
stimulation [123] and is itself involved in cleavage of Prl [124]; thus contributing to a 
positive feedback loop during lactation. Cathepsin D activity is inhibited by Serpin B5 
[125]. This could explain why Cathepsin D is not present in SCL stage, when Serpin B5 is 
found in higher levels. 
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Connective tissue growth factor was detected in high levels in D stage both at the 
mRNA [90] and extracellular protein levels. It has a role as cell adhesion molecule 
blocking anoikis and therefore it is a pro/survival factor [129].  
The exact function of Neutrophil gelatinase-associated lipocalin is not yet established, 
some authors consider that it could facilitate angiogenesis and tumour growth [133-134] 
while others consider that it could be correlated with apoptosis and cell survival [135]. 
However, and in agreement with these findings, Neutrophil gelatinase-associated lipocalin 
is only detected in differentiated PaCa cells but absent in poorly differentiated PaCa cells 
where it may have a role as suppressor of invasion [138]. 
Therefore, data obtained as cells differentiate point to pathways that inhibit invasion 
and increase survival, two fundamental processes in differentiation.  
 
In the attempt to study how ERβ function is affected in different cellular states ( i.e. 
influence with EGF/EGFR signalling or lactogenic hormone treatment) it was firstly 
compared the secretome of SCL cells (+EGF) and SCL cells as they begin the 
differentiation program (-EGF), when treated with the ERβ agonist DPN. Second, we 
compared the secretome of D cells treated with or without DPN. 
These results showed that in cells beginning to differentiate (-EGF) developmental 
processes (Basement membrane-specific heparan sulfate proteoglycan core protein, 
Ceruloplasmin and Periostin) and apoptosis processes (Galectin-3) are upregulated by ERβ 
when compared to SCL (+EGF). Therefore, it seems also clear that the tumour suppressor 
role of ERβ is only triggered on cells beginning to differentiate (-EGF). This indicates that 
in HC11 cells, ERβ effects are influenced by EGF/EGFR signalling. 
 
Independently of EGF prescence, ERβ activation leads to upregulation of SPARC 
which promotes migration and, in SCL +EGF, Fibronectin which is known to inhibit 
migration was downregulated. This indicates that in cells treated with DPN, EGF favours 
migratory signals which may be counteracted by Fibronectin in the absence of EGF; thus 
evidencing the tumour supressor role of ERβ which seems once again to be triggered when 
cells begin to differentiate (-EGF). 
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In functionally differentiated cells, ERβ activation lead to upregulation of Connective 
tissue growth factor, Insulin-like growth factor-binding protein 5, Cathepsin D, Collage 
alpha 1 (II) chain and Fibronectin. All these proteins are known to be present in 
differentiated cells and influence cell adhesion and/or apoptosis. Therefore, these results 
indicate that ERβ effects are dependent on the cell differentiation stage and that the 
clinically required tumour suppressor role of ERβ is only evidenced when SCL cells enter 
the differentiation program or are already fully differentiated. 
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Annexe 1 
 
 
 
 
 
 
 
 
 
 
Solutions  
 
Cell culture  
 
Complete medium:  
RPMI 1640, 
L-glutamine  
10% FBS  
50μl/ml gentamycin 
10ng/ml EGF 
5μl/ml insulin 
 
Serum free medium (SFM):  
RPMI 1640 (phenol red free) 
L-glutamine 
50μl/ml gentamycin 
5μl/ml insulin 
10ng/ml EGF (optional) 
 
Pre-differentiation medium:  
RPMI 1640, 
L-glutamine  
2 % FBS  
50μl/ml gentamycin 
5μl/ml insulin 
 
Differentiation medium:  
RPMI 1640, 
L-glutamine  
2 % FBS  
50μl/ml gentamycin 
5μl/ml insulin 
100 µM dexamethasone 
conc prolactin 
 
ER ligand treatment: stock solutions of 1 μM E2, 10 μM PPT and μM DPN were prepared 
in absolute ethanol and for treatment, they were diluted 1/1000 in serum free medium. 
Cells were treated for 24 h 
 
Protein precipitation and quantification 
 
Solution 1:  
PBS  
 0.1% Tween 20 
 1% SDS  
 1mM DTT 
 
Solution 2:  
8M Urea 
 2M Tiourea 
 1% CHAPS  
 10mg/ml DTT 
 
SDS-PAGE 
 
Running buffer 10X (before being used was diluted 1:10):  
0.25M Tris  
1.92M Glycine  
1% SDS  
Laemmli loading buffer (10mL):  
4mL SDS 10% 
2.5mL Tris 0.5M pH 6.8 
1.5mL Glycerol 
10.0mg Bromophenol Blue 
2.0mL Mercaptoetanol   
 
2D electrophoresis  
 
Rehydration buffer:  
8M Urea  
2M Tiourea  
1% CHAPS  
12.9mM DTT  
0.1% Pharmalyte 3-10  
0.01% Bromophenol Blue 
 
Equilibrium buffer (200ml):  
6.7ml electrophoresis buffer ph 8.8 
72.1g Urea 
69ml glycerol 87% 
 4g SDS 
Complete with distilled water 
 
0.5% Agar solution (100ml):  
0.5g Agar 
100ml running buffer 1X 
bromofenol blue   
 
Gel staining with Colloidal Coomassie (G250)  
 
Fixing solution:  
40% (v/v) methanol  
10% (v/v) acetic acid 
 
Colloidal coomassie:  
0.12% (w/v) coomassie blue G250 
20% methanol 
 
Destaining solution:  
25% methanol 
 
 
MALDI-TOF/TOF analysis  
 
Buf1: 50mM Ammonium bicarbonate  
FA: 10% (v/v) Formic acid  
Trypsin (v511, Promega): 1 vial solubilised in 2ml Buf1 
 
  
  
  
 
 
 
 
 
 
 
Annexe 2  
 
 
 
 
 
 
 
 
 
 
Comparison between –EGF control and +EGF control appear to show a higher intensity 
in –EGF control. However, when intensities are measure the 2 conditions show a similar 
value, -EGF CTR (39449 CNT*mm
2
) +EGF CTR (37825 CNT*mm
2
). This effect was 
observed in other 1D electrophoresis.  
 
 
 
 
 
  
-EGF 
CTR 
+EGF 
CTR 
  
 
 
 
 
 
 
 
Annexe 3 
 
 
 
 
 
 
 
 
 
 
Table 1- Proteins expressed in Proliferation (SCL +EGF) identify by SDS-PAGE MALDI-TOF/TOF 
Nº identifications Protein name 
Accession 
number 
Protein 
MW (Da) 
Protein PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological 
process 
2 
 
14-3-3 protein epsilon  P62259 29155 4,63 10 100,00 mitochondrion cell cycle 
3 
14-3-3 protein zeta/delta P63102 27754 4,73 13 100,00 Cytoplasm cell cycle 
1 
78 kDa glucose-regulated 
protein  P20029 72377 5,07 20 100,00 Cytoplasm 
response to 
stimulus 
5 Actin, cytoplasmic 2 P63259 41766 5,31 11 100,00 Cytoplasm 
cellular component 
organization 
1 Alpha-actinin-1  Q7TPR4 103004 5,25 19 100,00 Cytoplasm 
cellular component 
organization 
1 Alpha-actinin-4  P57780 104911 5,25 19 100,00 Cytoplasm 
cellular component 
organization 
3 
Alpha-enolase  P17182 47111 6,37 8 100,00 Secreted metabolic process 
1 
Annexin A2  P07356 38652 7,55 11 100,00  Secreted cell comunnication 
3 Beta-actin-like protein 2  Q8BFZ3 41977 5,3 8 100,00 Cytoplasm 
cellular component 
organization 
1 
Coagulation factor VIII  Q06194 265981 6,9 17 96,47 Extracellular matrix cell comunnication 
3 
Collagen alpha-1(VI) 
chain  Q04857 108422 5,2 9 100,00 Extracellular matrix cell comunnication 
Table 2- Proteins expressed in Proliferation (SCL +EGF) identify by SDS-PAGE MALDI-TOF/TOF (Cont.) 
Nº identifications Protein name 
Accession 
number 
Protein 
MW (Da) 
Protein PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological 
process 
1 
Elongation factor 1-alpha 
1  P10126 50082 9,1 7 99,97 Cytoplasm cellular process 
4 
Elongation factor 2  P05197 95223 6,41 13 100,00 Cytoplasm cellular process 
1 
Extracellular superoxide 
dismutase [Cu-Zn]  O09164 27375 6,36 3 99,24 Secreted   
1 
Fatty acid synthase  P19096 272257 6,13 15 100,00 Mitochondrion metabolic process 
2 
Fibronectin  P11276 272319 5,39 30 100,00 Secreted cell comunnication 
1 
Fructose-bisphosphate 
aldolase A  P05064 39331 8,31 11 100,00 flagellum metabolic process 
1 
Heat shock cognate 71 
kDa protein  P63018 70827 5,37 19 100,00 Cytoplasm 
response to 
stimulus 
1 
Heat shock protein HSP 
90-alpha  P07901 84735 4,93 9 100,00 Cytoplasm 
response to 
stimulus 
3 
Heat shock protein HSP 
90-beta  P11499 83273 4,97 16 100,00 Cytoplasm 
response to 
stimulus 
1 
Homeobox protein 
Rhox5  P52651 23031 5,92 9 95,89 Nucleus   
1 
Malate dehydrogenase, 
cytoplasmic  P14152 36488 6,16 3 96,28 Cytoplasm metabolic process 
Table 3- Proteins expressed in Proliferation (SCL +EGF) identify by SDS-PAGE MALDI-TOF/TOF (Cont.) 
Nº identifications Protein name 
Accession 
number 
Protein 
MW (Da) 
Protein PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological 
process 
1 
Peroxiredoxin-1  P35700 22162 8,26 7 100,00 Cytoplasm metabolic process 
1 
Phosphoglycerate kinase 
1 * P09411 44522 8,02 9 100,00 Cytoplasm metabolic process 
1 
Proteasome subunit beta 
type-1  O09061 26355 7,67 4 100,00 Cytoplasm metabolic process 
3 
Protein disulfide-
isomerase  P09103 57108 4,79 13 100,00 Cell membrane metabolic process 
5 
Pyruvate kinase 
isozymes M1/M2  P52480 57808 7,18 16 100,00 Cytoplasm metabolic process 
1 
Rho GDP-dissociation 
inhibitor 1  Q99PT1 23393 5,12 10 100,00 cytoplasm cellular process 
6 
Serum albumin  P07724 68648 5,75 8 100,00 Secreted transport 
1 Thrombospondin-1  P35441 129564 4,72 8 99,67 Extracellular matrix 
response to 
stimulus 
1 Tubulin alpha-1C chain P68373 49877 4,96 5 100,00 Cytoplasm 
cellular component 
organization 
 Table 2 - Proteins expressed in Pre-diffentiation 48h identify by SDS-PAGE MALDI-TOF/TOF 
Nº identifications Protein name 
Accession 
number 
Protein 
MW (Da) 
Protein PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological 
process 
1 
 
Calsyntenin-1  Q9EPL2 108831 4,82 4 99,97 Extracellular matrix cell comunnication 
1 
Fibronectin  P11276 272319 5,39 35 100,00 Extracellular matrix cell comunnication 
1 
Metalloproteinase 
inhibitor 2  P25785 24312 7,45 5 100,00 Extracellular matrix metabolic process 
1 
Neutrophil gelatinase-
associated lipocalin P11672 22861 8,96 2 100,00 Secreted cell comunnication 
1 
Periostin  Q62009 93085 7,27 8 100,00 Extracellular matrix cell comunnication 
1 
Protein disulfide-
isomerase  P09103 57108     100,00 Cell membrane metabolic process 
1 
Pyruvate kinase 
isozymes M1/M2  P52480 57808 7,18 6 100,00 Cytoplasm metabolic process 
 
 
 
 
 
 
Table 3 - Proteins expressed in Diffentiation identify by SDS-PAGE MALDI-TOF/TOF 
Nº identifications Protein name 
Accession 
number 
Protein 
MW (Da) 
Protein PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological 
process 
1 
78 kDa glucose-regulated 
protein  P20029 72377 5,07 11 99,86 
Endoplasmic 
reticulum 
response to 
stimulus 
1 
Actin, alpha skeletal 
muscle  P68136 42024 5,23 5 100,00 Cytoplasm 
cellular component 
organization 
1 Actin, cytoplasmic 2  P68138 41766 5,31 10 100,00 Cytoplasm 
cellular component 
organization 
1 Alpha-actinin-4  P57780 104911 5,25 10 99,77 Cytoplasm 
cellular component 
organization 
1 
Alpha-enolase  P17182 47111 6,37 9 100,00 Secreted metabolic process 
3 
Annexin A2  P07356 38652 7,55 15 100,00 Secreted cellular process 
2 
Annexin A5  P48036 35730 4,83 16 100,00 Plasma membrane cell comunnication 
1 
ATP synthase subunit 
beta, mitochondrial  P56480 56265 5,19 6 100,00 Mitochondrion metabolic process 
2 Beta-actin-like protein 2  Q8BFZ4 41977 5,3 5 100,00 Cytoplasm 
cellular component 
organization 
1 
Calicin  Q8CDE2 66707 8,49 5 96,93 Cytoplasm metabolic process 
1 
Cathepsin D  P18242 44925 6,71 4 99,91 Lysosome metabolic process 
 
Table 3 - Proteins expressed in Diffentiation identify by SDS-PAGE MALDI-TOF/TOF (Cont.) 
Nº identifications Protein name 
Accession 
number 
Protein 
MW (Da) 
Protein PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological 
process 
1 
Ceruloplasmin  Q61147 121074 5,53 16 100,00 Secreted cell comunnication 
2 
Collagen alpha-1(II) 
chain  P28482 141886 6,58 32 100,00 Extracellular matrix cell comunnication 
2 
Complement C3 P01027 186365 6,39 22 100,00 Secreted cell comunnication 
2 
Connective tissue growth 
factor  P29268 37768 8,22 2 99,90 Extracellular matrix cell comunnication 
1 
Elongation factor 1-alpha 
1  P10126 50082 9,1 3 95,13 Cytoplasm cellular process 
2 
Fibronectin  P11276 272319 5,39 33 100,00 Extracellular matrix cell comunnication 
1 Galectin-3 P16110 27498 8,46 6 99,82 
 Extracellular 
matrix cellular process 
2 
Heat shock cognate 71 
kDa protein  P63017 70827 5,37 16 100,00 Cytoplasm 
response to 
stimulus 
1 
Heat shock-related 70 
kDa protein 2  P17156 69698 5,58 9 99,99 Cytoplasm 
response to 
stimulus 
1 
Hexokinase-1  P17710 108233 6,44 14 99,99 Mitochondrion metabolic process 
1 
Histone H2A type 1-F  Q8CGP5 14153 11,05 5 100,00 nucleus cellular process 
 
Table 3 - Proteins expressed in Diffentiation identify by SDS-PAGE MALDI-TOF/TOF (Cont.) 
Nº identifications Protein name 
Accession 
number 
Protein 
MW (Da) 
Protein PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological 
process 
1 
Histone H2A type 1-H  Q8CGP6 13942 11,03 3 99,96 nucleus cellular process 
1 
Histone H3.1  Q6LBF0 15394 11,13 9 100,00 nucleus cellular process 
1 
Histone H4  P62804 11360 11,36 9 100,00 nucleus cellular process 
2 
Insulin-like growth 
factor-binding protein 5  Q07079 30353 8,48 5 100,00 Secreted cell comunnication 
1 
Keratin, type I 
cytoskeletal 14  Q61781 52834 5,1 9 100,00 Sarcolemma 
cellular component 
organization 
1 
Keratin, type II 
cytoskeletal 73  Q6NXH9 58875 8,36 7 96,08 Cytoplasm 
cellular component 
organization 
1 
Malate dehydrogenase, 
mitochondrial  P04636 35661 8,93 4 100,00 Mitochondrion metabolic process 
2 
Neutrophil gelatinase-
associated lipocalin  P11672 22861 8,96 6 100,00 Secreted cell comunnication 
3 
Periostin  Q62009 93085 7,27 25 100,00 Secreted cell comunnication 
2 
Protein disulfide-
isomerase  P09103 57108 4,79 9 100,00 Cell membrane metabolic process 
1 
Pyruvate kinase 
isozymes M1/M2  P52480 57808 7,18 12 100,00 Cytoplasm cell comunnication 
 
Table 3 - Proteins expressed in Diffentiation identify by SDS-PAGE MALDI-TOF/TOF (Cont.) 
Nº identifications Protein name 
Accession 
number 
Protein 
MW (Da) 
Protein PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological 
process 
1 
Rho GDP-dissociation 
inhibitor 1  Q5XI73 23393 5,12 7 100,00 Cytoplasm cellular process 
5 
Serum albumin  P07724 68648 5,75 8 100,00 Secreted transport 
1 
Sex comb on midleg-like 
protein 4  Q80VG1 44417 9,81 9 99,25 nucleus cell cycle 
2 
SPARC  P07214 34428 4,77 11 100,00 Extracellular matrix cell comunnication 
1 
TRIO and F-actin-
binding protein  Q99KW3 223232 8,36 21 99,76 Cytoplasm cell comunnication 
1 Tubulin alpha-1C chain  P68373 49877 4,96 7 100,00 Cytoplasm 
cellular component 
organization 
1 Tubulin beta-5 chain  P99024 49639 4,78 11 98,29 Cytoplasm 
cellular component 
organization 
 
 
 
 
 
 
 
Table 4 - Proteins expressed in Pre-diffentiation 24h identify by SDS-PAGE MALDI-TOF/TOF 
Nº identifications Protein name 
Accession 
number 
Protein 
MW (Da) 
Protein PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological 
process 
1 
14-3-3 protein sigma  O70456 27696 4,75 8 99,99 Secreted cell cycle 
1 
78 kDa glucose-regulated 
protein  P06761 72302 5,07 17 100,00 Cytoplasm 
response to 
stimulus 
1 Actin, cytoplasmic 2  P63260 41766 5,31 9 100,00 Cytoplasm 
cellular component 
organization 
1 Alpha-actinin-4  P57780 104911 5,25 12 100,00 Cytoplasm 
cellular component 
organization 
3 
Alpha-enolase  P17182 47111 6,37 13 100,00 Secreted metabolic process 
1 
Annexin A3  O35639 36349 5,33 8 100,00 Cell membrane cell comunnication 
2 
Calsyntenin-1  Q9EPL3 108831 5 11 100,00 Extracellular matrix cell comunnication 
1 
Cathepsin D  P18242 44925 6,71 7 99,91 Secreted metabolic process 
1 
Ceruloplasmin  Q61147 121074 5,53 10 99,15 Extracellular matrix cell comunnication 
1 
Collagen alpha-1(II) 
chain  P28481 141886 6,58 32 100,00 Extracellular matrix cell comunnication 
1 
Collagen alpha-1(XI) 
chain  Q61245 180853 5,09 7 100,00 Extracellular matrix cell comunnication 
 
Table 4 - Proteins expressed in Pre-diffentiation 24h identify by SDS-PAGE MALDI-TOF/TOF (Cont.) 
Nº 
identifications 
Protein name 
Accession 
number 
Protein 
MW (Da) 
Protein PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological 
process 
1 
Cystatin-C  P21460 15521 9,18 9 100,00 Extracellular matrix metabolic process 
1 
Double-stranded RNA-binding 
protein Staufen homolog 2  Q8CJ67 62496 9,61 10 99,19 
endoplasmic 
reticulum cell cycle 
1 
Elongation factor 1-alpha 1  P10126 50082 9,1 1 98,77 Cytoplasm cellular process 
1 
Elongation factor 1-gamma  Q9D8N0 50029 6,31 7 99,60 Cytoplasm cellular process 
5 
Elongation factor 2  P58252 95223 6,41 17 100,00 Cytoplasm cellular process 
1 Fibronectin  P11276 272319 5,39 33 100,00 Secreted 
cell 
comunnication 
1 
Fructose-bisphosphate aldolase 
A  P05064 39331 8,31 8 100,00 Cytoplasm metabolic process 
1 
Glyceraldehyde-3-phosphate 
dehydrogenase  P16858 35787 8,44 4 100,00 Cytoplasm metabolic process 
1 
Heat shock cognate 71 kDa 
protein  P19378 70761 5,24 17 100,00 Cytoplasm 
response to 
stimulus 
4 Heat shock protein HSP 90-beta  P11499 83273 4,97 22 100,00 Cytoplasm 
response to 
stimulus 
1 
Insulin-like growth factor-
binding protein 5  Q07079 30352 8,48 6 99,80 Secreted 
cell 
comunnication 
 
Table 4 - Proteins expressed in Pre-diffentiation 24h identify by SDS-PAGE MALDI-TOF/TOF (Cont.) 
Nº identifications Protein name 
Accession 
number 
Protein 
MW (Da) 
Protein PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological 
process 
1 
Liprin-alpha-3  P58252 95223 6,41 17 100,0 Cytoplasm cellular process 
1 
Malate dehydrogenase, 
cytoplasmic P11276 272319 5,39 33 100,0 Secreted. cell comunnication 
1 
MyoD family inhibitor  P16858 35787 8,44 4 100,0 Cytoplasm metabolic process 
1 
Neutrophil gelatinase-
associated lipocalin  P19378 70761 5,24 17 100,0 Cytoplasm 
response to 
stimulus 
1 Periostin  P11499 83273 4,97 22 100,0 Cytoplasm 
response to 
stimulus 
2 
Phosphoglycerate kinase 
1  P60469 116208 5,72 4 98,0 cell surface cellular process 
1 
Protein disulfide-
isomerase  P09411 44522 8 4 100,0 Cytoplasm metabolic process 
6 
Serum albumin P07724 68648 5,75 6 100,0 Secreted transport 
1 
SPARC  P07214 34428 4,77 10 100,00 Extracellular matrix cell comunnication 
 
 
 
 
 
 
 
Table 5 - Proteins expressed by HC11 cells under estrogenic stimulation with or without EGFR activation identify by 2D-PAGE MALDI-TOF/TOF 
Protein name 
Accession 
number 
Protein MW 
(Da) 
Protein 
PI 
Peptide 
count 
Protein Score 
C.I. (%) 
Subcellular location Biological process 
14-3-3 protein gamma P61983 28285 4,8 2 99,81 Cytoplasm cell cycle 
14-3-3 protein zeta/delta P63102 27754 4,73 8 100,00 Cytoplasm cell cycle 
40S ribosomal protein SA P14206 32817 4,8 3 100,00 nucleus metabolic process 
60 kDa heat shock protein, mitochondrial P63039 60917 5,91 1 99,99 Cytoplasm metabolic process 
6-phosphogluconate dehydrogenase, 
decarboxylating 
Q9DCD0 53213 6,81 3 100,00 extracellular matrix metabolic process 
78 kDa glucose-regulated protein P20029 72377 5,07 13 99,97 Cytoplasm response to stimulus 
Actin, cytoplasmic 1 P48975 41711 5,22 1 100,00 cytoskeleton 
cellular component 
organization 
Actin-related protein 2/3 complex subunit 2 Q9CVB6 34336 6,84 1 96,55 cytoskeleton 
cellular component 
organization 
Actin-related protein 3 Q4V7C7 47327 5,61 3 96,71 cytoskeleton 
cellular component 
organization 
Acyl-coenzyme A thioesterase 3 Q9QYR7 47460 6,98 2 100,00 Cytoplasm metabolic process 
Alpha-actinin-4 P57780 104911 5,25 4 99,34 cytoskeleton 
cellular component 
organization 
Alpha-centractin P85515 42587 6,19 3 100,00 cytoskeleton 
cellular component 
organization 
 
Table 5 - Proteins expressed by HC11 cells under estrogenic stimulation with or without EGFR activation identify by 2D-PAGE MALDI-TOF/TOF (Cont.) 
Protein name 
Accession 
number 
Protein MW 
(Da) 
Protein 
PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological process 
Alpha-enolase P17182 47111 6,37 16 100,00 Secreted metabolic process 
Annexin A3 O35639 36349 5,33 11 100,00 Cell membrane cell comunnication 
Annexin A8 O35640 36820 5,56 2 100,00  cell comunnication 
Aspartate aminotransferase, cytoplasmic P05201 46202 6,68 8 100,00 Cytoplasm metabolic process 
Aspartate aminotransferase, mitochondrial P00507 47284 9,13 3 97,26 Mitochondrion metabolic process 
Basement membrane-specific heparan sulfate proteoglycan core 
protein 
Q05793 398039 5,88 2 100,00 
extracellular 
matrix 
cell comunnication 
Beta-actin-like protein 2 Q8BFZ3 41977 5,3 3 100,00 cytoskeleton 
cellular component 
organization 
Beta-centractin Q8R5C5 42255 5,98 1 98,63 cytoskeleton 
cellular component 
organization 
Bifunctional purine biosynthesis protein PURH Q9CWJ9 64177 6,3 10 100,00 Mitochondrion metabolic process 
Calreticulin P14211 47965 4,33 1 99,99 
extracellular 
matrix 
metabolic process 
Ceruloplasmin Q61147 121074 5,53 7 100,00 Secreted cell comunnication 
Chloride intracellular channel protein 1 Q6MG61 26964 5,09 2 100,00 cytoskeleton cell comunnication 
 
 
  
 
 
Table 5 - Proteins expressed by HC11 cells under estrogenic stimulation with or without EGFR activation identify by 2D-PAGE MALDI-TOF/TOF (Cont.) 
Protein name 
Accession 
number 
Protein MW 
(Da) 
Protein 
PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological process 
Cofilin-1 P45592 18521 8,22 3 100,00 cytoskeleton 
cellular component 
organization 
Complement C3 P01027 186365 6,39 2 100,00 Secreted cell comunnication 
E3 ubiquitin-protein ligase NEURL3 Q8CJC5 28022 6,45 3 97,77   
Elongation factor 1-alpha 1 P10126 50082 9,1 7 99,98 Cytoplasm cellular process 
Elongation factor 1-beta O70251 24678 4,53 1 100,00 Cytoplasm cellular process 
Elongation factor 1-gamma Q9D8N0 50029 6,31 3 98,42 Cytoplasm cellular process 
Elongation factor 2 P58252 95253 6,41 16 100,00 Cytoplasm cellular process 
Endoplasmin P08113 92418 4,74 10 100,00 
endoplasmic 
reticulum 
metabolic process 
Eukaryotic initiation factor 4A-II P10630 46373 5,33 1 99,97  metabolic process 
Eukaryotic translation initiation factor 3 subunit I B0BNA7 36438 5,38 2 99,92 Cytoplasm metabolic process 
Eukaryotic translation initiation factor 5A-1 Q3T1J1 16821 5,08 1 97,83 Cytoplasm metabolic process 
Eukaryotic translation initiation factor 6 Q3KRD8 26554 4,63 3 100,00 Cytoplasm metabolic process 
Table 5 - Proteins expressed by HC11 cells under estrogenic stimulation with or without EGFR activation identify by 2D-PAGE MALDI-TOF/TOF (Cont.) 
Protein name 
Accession 
number 
Protein MW 
(Da) 
Protein 
PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological process 
Extracellular superoxide dismutase [Cu-Zn] O09164 27375 6,36 1 95,46 Secreted  
F-actin-capping protein subunit alpha-1 P47753 32919 5,34 3 99,99 cytoskeleton 
cellular component 
organization 
F-actin-capping protein subunit alpha-2 Q3T1K5 32947 5,57 6 100,00 cytoskeleton 
cellular component 
organization 
Fascin P85845 54457 6,29 3 97,13 Cell projection 
cellular component 
organization 
Fructose-bisphosphate aldolase A P05064 39331 8,31 8 100,00 flagellum metabolic process 
Galectin-3 P16110 27498 8,46 6 100,00 
extracellular 
matrix 
cellular process 
Glucose-6-phosphate 1-dehydrogenase X Q00612 59225 6,06 8 100,00  metabolic process 
Glutaredoxin-3 Q9JLZ1 37825 5,51 1 99,99 Cytoplasm metabolic process 
Glutathione S-transferase P 1 P19157 23594 7,68 4 100,00 Cytoplasm response to stimulus 
Glyceraldehyde-3-phosphate dehydrogenase P16858 35787 8,44 4 100,00 Cytoplasm metabolic process 
Heat shock 70 kDa protein 1B P17879 70133 5,53 12 99,63 Cytoplasm response to stimulus 
Heat shock 70 kDa protein 4 Q61316 94073 5,15 8 100,00 Cytoplasm response to stimulus 
 
 
Table 5 - Proteins expressed by HC11 cells under estrogenic stimulation with or without EGFR activation identify by 2D-PAGE MALDI-TOF/TOF (Cont.) 
Protein name 
Accession 
number 
Protein MW 
(Da) 
Protein 
PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological process 
Heat shock protein beta-1 P14602 23000 6,12 3 100,00 Cytoplasm response to stimulus 
Heat shock protein HSP 90-alpha P07901 84762 4,93 4 100,00 Cytoplasm response to stimulus 
Heat shock protein HSP 90-beta P11499 83273 4,97 6 100,00 Cytoplasm response to stimulus 
Heat shock-related 70 kDa protein 2 P17156 69698 5,58 7 96,22 Cytoplasm response to stimulus 
Heterogeneous nuclear ribonucleoprotein A/B Q99020 30812 7,68 11 100,00 
ribonucleoprotein 
complex 
cellular process 
Heterogeneous nuclear ribonucleoprotein A1 P04256 34191 9,2 4 100,00 
ribonucleoprotein 
complex 
cellular process 
Heterogeneous nuclear ribonucleoprotein F Q794E4 45701 5,31 1 100,00 
ribonucleoprotein 
complex 
cellular process 
Heterogeneous nuclear ribonucleoproteins A2/B1 A7VJC2 37455 8,97 3 100,00 
ribonucleoprotein 
complex 
cellular process 
Inorganic pyrophosphatase Q9D819 32646 5,37 7 100,00 Cytoplasm metabolic process 
Keratin, type II cytoskeletal 8 P11679 54531 5,7 2 100,00 cytoskeleton 
cellular component 
organization 
Lactoylglutathione lyase Q9CPU0 20796 5,24 3 99,98   
Macrophage-capping protein P24452 39216 6,73 4 100,00 cytoskeleton 
cellular component 
organization 
Table 5 - Proteins expressed by HC11 cells under estrogenic stimulation with or without EGFR activation identify by 2D-PAGE MALDI-TOF/TOF (Cont.) 
Protein name 
Accession 
number 
Protein MW 
(Da) 
Protein 
PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological process 
Malate dehydrogenase, cytoplasmic P14152 36460 6,16 1 100,00 Cytoplasm metabolic process 
Malate dehydrogenase, mitochondrial P04636 35661 8,93 4 100,00 Mitochondrion metabolic process 
Metalloproteinase inhibitor 2 P25785 24340 7,45 2 100,00 
Extracellular 
matrix 
metabolic process 
Multifunctional protein ADE2 Q9DCL9 47040 6,94 2 100,00  metabolic process 
Neutrophil gelatinase-associated lipocalin P11672 22861 8,96 3 100,00 Secreted. cell comunnication 
Nucleolin P08199 77082 4,7 4 96,31 Cytoplasm  
Nucleoside diphosphate kinase B Q01768 17352 6,97 6 100,00 Mitochondrion metabolic process 
Obg-like ATPase 1 Q9CZ30 44701 7,64 3 100,00   
Peptidyl-prolyl cis-trans isomerase D Q6DGG0 40740 6,73 6 100,00 Cytoplasm metabolic process 
Periostin Q62009 93085 7,27 25 100,00 Secreted cell comunnication 
Peroxiredoxin-1 P35700 22162 8,26 5 100,00 Cytoplasm metabolic process 
Peroxiredoxin-6 O08709 24855 5,71 3 100,00 Cytoplasm metabolic process 
 
 
 
 
 
 
Table 5 - Proteins expressed by HC11 cells under estrogenic stimulation with or without EGFR activation identify by 2D-PAGE MALDI-TOF/TOF (Cont.) 
Protein name 
Accession 
number 
Protein MW 
(Da) 
Protein 
PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological process 
Phosphatidylethanolamine-binding protein 1 P70296 20817 5,19 4 100,00 Cytoplasm cellular process 
Phosphatidylinositol transfer protein alpha isoform P16446 31887 5,97 1 99,99 Cytoplasm metabolic process 
Phosphoglycerate kinase 1 P09411 44522 8,02 16 100,00 Cytoplasm metabolic process 
Phosphoserine aminotransferase Q99K85 40447 8,15 11 100,00  metabolic process 
Pre-mRNA-processing factor 19 Q9JMJ4 55204 6,14 3 99,58 Cytoplasm metabolic process 
Proliferating cell nuclear antigen P17918 28766 4,66 2 100,00 nucleus cell cycle 
Proteasome activator complex subunit 1 P97371 28655 5,73 7 100,00 Cytoplasm metabolic process 
Proteasome subunit alpha type-5 Q9Z2U1 26394 4,74 4 100,00 Cytoplasm metabolic process 
Proteasome subunit alpha type-7 Q9Z2U0 27838 8,59 7 100,00 Cytoplasm metabolic process 
Proteasome subunit beta type-3 P40112 22949 6,15 1 100,00 Cytoplasm metabolic process 
Proteasome subunit beta type-5 O55234 28514 6,52 3 99,96 Cytoplasm metabolic process 
Protein disulfide-isomerase P09103 57108 4,79 7 100,00 cell membranne metabolic process 
 
 
 
 
 
 
Table 5 - Proteins expressed by HC11 cells under estrogenic stimulation with or without EGFR activation identify by 2D-PAGE MALDI-TOF/TOF (Cont.) 
Protein name 
Accession 
number 
Protein MW 
(Da) 
Protein 
PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological process 
Protein disulfide-isomerase A3 P27773 56643 5,88 5 100,00 
endoplasmic 
reticulum 
metabolic process 
Protein disulfide-isomerase A6 Q922R8 48070 5 6 100,00 cell membranne metabolic process 
Protein SET Q63945 33386 4,22 2 99,41 Cytoplasm cell cycle 
Pyruvate kinase isozymes M1/M2 P52480 57808 7,18 10 100,00 Cytoplasm metabolic process 
Renin receptor Q9CYN9 39067 5,36 3 100,00 Cell membrane cell comunnication 
Rho GDP-dissociation inhibitor 1 Q99PT1 23393 5,12 8 100,00 cytoplasm cellular process 
Scavenger mRNA-decapping enzyme DcpS Q9DAR7 38964 6,02 2 100,00 cytoplasm metabolic process 
Septin-2 Q91Y81 41566 6,15 3 100,00 cytoskeleton cell cycle 
Septin-7 Q9WVC0 50476 8,82 6 100,00 cytoskeleton cell cycle 
Serpin B5 P70124 42085 5,55 7 100,00 Secreted. metabolic process 
Serum albumin P07724 68648 5,75 4 97,00 Secreted transport 
S-formylglutathione hydrolase Q9R0P3 31299 6,7 1 99,96 Cytoplasm  
 
 
 
 
 
Table 5 - Proteins expressed by HC11 cells under estrogenic stimulation with or without EGFR activation identify by 2D-PAGE MALDI-TOF/TOF (Cont.) 
Protein name 
Accession 
number 
Protein MW 
(Da) 
Protein 
PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological process 
SPARC P07214 34428 4,77 3 99,82 
Extracellular 
matrix 
cell comunnication 
Stress-induced-phosphoprotein 1 Q60864 62542 6,4 10 100,00 Cytoplasm response to stimulus 
T-complex protein 1 subunit alpha (Fragments) P86208 13403 5,13 3 96,47 Cytoplasm metabolic process 
T-complex protein 1 subunit beta P80314 57441 5,97 10 100,00 Cytoplasm metabolic process 
Thioredoxin-like protein 1 Q920J4 32229 4,84 1 100,00 Cytoplasm cell comunnication 
Tight junction-associated protein 1 Q9DCD5 59383 5,74 7 95,46 tight junction  
Transketolase P40142 67588 7,23 13 100,00  metabolic process 
Tropomyosin alpha-3 chain P21107 32843 4,68 2 95,66 cytoskeleton 
cellular component 
organization 
Tropomyosin alpha-4 chain Q6IRU2 28450 4,65 2 100,00 cytoskeleton 
cellular component 
organization 
Tubulin alpha-1C chain P68373 49877 4,96 2 100,00 cytoskeleton 
cellular component 
organization 
Tubulin alpha-4A chain Q5XIF6 49892 4,95 3 100,00 cytoskeleton 
cellular component 
organization 
Ubiquitin carboxyl-terminal hydrolase isozyme L3 Q9JKB1 26135 4,96 5 99,93 Cytoplasm metabolic process 
 
Table 5 - Proteins expressed by HC11 cells under estrogenic stimulation with or without EGFR activation identify by 2D-PAGE MALDI-TOF/TOF (Cont.) 
Protein name 
Accession 
number 
Protein MW 
(Da) 
Protein 
PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological process 
Ubiquitin-conjugating enzyme E2 K P61087 22393 5,33 7 100,00 Cytoplasm metabolic process 
UPF0760 protein C2orf29 homolog Q9CWN7 54924 6,11 7 95,56   
UTP--glucose-1-phosphate uridylyltransferase Q91ZJ5 56944 7,18 3 100,00 Cytoplasm metabolic process 
Zinc finger protein 664 Q4VA44 30305 9,03 5 97,20 nucleus metabolic process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7 - Proteins expressed in Diffentiation identify by 2D-PAGE MALDI-TOF/TOF 
Protein name 
Accession 
number 
Protein MW 
(Da) 
Protein 
PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological process 
14-3-3 protein epsilon P62259 29155 4,63 5 100,00 mitochondrion cell cycle 
14-3-3 protein gamma P61983 28285 4,8 4 99,99 Cytoplasm cell cycle 
14-3-3 protein theta P68255 27761 4,69 10 100,00 Cytoplasm cell cycle 
14-3-3 protein zeta/delta P63102 27754 4,73 11 100,00 Cytoplasm cell cycle 
78 kDa glucose-regulated protein P20029 72377 5,07 27 100,00 Cytoplasm response to stimulus 
Actin, cytoplasmic 1 P48975 41711 5,22 10 100,00 cytoskeleton 
cellular component 
organization 
Annexin A5 P48036 35730 4,83 19 100,00 membrane cell comunnication 
Cadherin-1 P09803 98195 4,69 5 100,00 Cell membrane cellular process 
Calmodulin P62161 16827 4,09 3 100,00 Cytoplasm  
Calreticulin P14211 47965 4,33 16 100,00 
extracellular 
matrix 
metabolic process 
Carboxypeptidase E Q00493 53222 5,07 10 100,00 Secreted metabolic process 
Chloride intracellular channel protein 1 Q6MG61 26964 5,09 9 100,00 cytoskeleton cell comunnication 
 
 
 
 
Table 7 - Proteins expressed in Diffentiation identify by 2D-PAGE MALDI-TOF/TOF (Cont.) 
Protein name 
Accession 
number 
Protein MW 
(Da) 
Protein 
PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological process 
Coatomer subunit epsilon O89079 34545 4,94 2 99,83 Cytoplasm transport 
Dynactin subunit 2 Q99KJ8 44090 5,14 6 100,00 Cytoplasm  
EF-hand domain-containing protein D2 Q9D8Y0 26775 5,01 9 100,00 cell membrane cellular process 
Elongation factor 1-delta P57776 31274 4,91 5 100,00 Cytoplasm cellular process 
Endoplasmin P08113 92418 4,74 9 99,98 
endoplasmic 
reticulum 
metabolic process 
Eukaryotic translation initiation factor 2 subunit 1 P68101 36085 5,02 6 100,00 Cytoplasm metabolic process 
Eukaryotic translation initiation factor 5A-1 Q3T1J1 16821 5,08 5 99,98 Cytoplasm metabolic process 
F-actin-capping protein subunit alpha-1 P47753 32919 5,34 4 99,47 cytoskeleton 
cellular component 
organization 
Heat shock protein HSP 90-alpha P07901 84735 4,93 8 100,00 Cytoplasm response to stimulus 
Heat shock protein HSP 90-beta P11499 83273 4,97 18 100,00 Cytoplasm response to stimulus 
Heterogeneous nuclear ribonucleoprotein F Q794E4 45701 5,31 5 100,00 
ribonucleoprotein 
complex 
cellular process 
Inositol monophosphatase 1 O55023 30416 5,08 6 100,00 Cytoplasm metabolic process 
 
 
 
Table 7 - Proteins expressed in Diffentiation identify by 2D-PAGE MALDI-TOF/TOF (Cont.) 
Protein name 
Accession 
number 
Protein MW 
(Da) 
Protein 
PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological process 
Microtubule-associated protein RP/EB family member 1 Q61166 29997 5,12 9 100,00 cytoskeleton cell cycle 
Nascent polypeptide-associated complex subunit alpha Q60817 23370 4,52 5 100,00 Cytoplasm transport 
Proliferating cell nuclear antigen P17918 28766 4,66 1 96,71 nucleus cell cycle 
Prostate and testis expressed protein 3 B3GLJ3 11652 9,14 5 97,92 Secreted  
Proteasome subunit alpha type-3 P18422 28401 5,29 8 100,00 Cytoplasm metabolic process 
Protein disulfide-isomerase P09103 57108 4,79 18 100,00 cell membranne metabolic process 
Protein disulfide-isomerase A6 Q922R8 48143 5 6 99,93 cell membranne metabolic process 
Protein SET Q63945 33386 4,22 11 100,00 Cytoplasm cell cycle 
Ran-specific GTPase-activating protein P34022 23582 5,15 9 100,00 nucleus  
Renin receptor Q9CYN9 39067 5,36 6 100,00 Cell membrane cell comunnication 
Rho GDP-dissociation inhibitor 1 Q99PT1 23393 5,12 3 99,11 cytoplasm cellular process 
Serine-threonine kinase receptor-associated protein Q5XIG8 38432 4,99 3 100,00 cytoplasm cellular process 
 
 
 
 
 
 
Table 7 - Proteins expressed in Diffentiation identify by 2D-PAGE MALDI-TOF/TOF (Cont.) 
Protein name 
Accession 
number 
Protein MW 
(Da) 
Protein 
PI 
Peptide 
count 
Protein 
Score C.I. 
(%) 
Subcellular 
location 
Biological process 
SPARC P07214 34428 4,77 5 100,00 Extracellular matrix cell comunnication 
S-phase kinase-associated protein 1 Q9WTX5 18660 4,4 3 100,00 cytoplasm cellular process 
SUMO-activating enzyme subunit 1 Q9R1T2 38596 5,24 8 100,00 nucleus cellular process 
Thioredoxin-like protein 1 Q920J4 32229 4,84 9 100,00 Cytoplasm cell comunnication 
Thrombospondin-1 P35441 129564 4,72 11 100,00 Extracellular matrix response to stimulus 
Translationally-controlled tumor protein P63029 19450 4,76 4 100,00 Cytoplasm 
cellular component 
organization 
Tropomyosin alpha-1 chain P58771 32661 4,69 2 99,71 cytoskeleton 
cellular component 
organization 
Tropomyosin alpha-3 chain P21107 32843 4,68 11 100,00 cytoskeleton 
cellular component 
organization 
Tropomyosin alpha-4 chain Q6IRU2 28450 4,65 12 100,00 cytoskeleton 
cellular component 
organization 
Tubulin alpha-1C chain P68373 49877 4,96 15 100,00 Cytoplasm 
cellular component 
organization 
Tubulin beta-5 chain P99024 49639 4,78 13 100,00 Cytoplasm 
cellular component 
organization 
 
